{"Title": ["Ligand's Icagen Expands License Agreement With Roche - Quick Facts", "LGND Crosses Below Key Moving Average Level", "Notable Thursday Option Activity: INVA, CSOD, LGND", "Ligand Pharmaceuticals Inc (LGND) Q1 2020 Earnings Call Transcript", "Ligand Pharmaceuticals Inc Q1 adjusted earnings Beat Estimates", "Ligand Pharmaceuticals Q1 20 Earnings Conference Call At 4:30 PM ET", "Noteworthy Monday Option Activity: LGND, OPK, KSU", "Validea's Top Five Healthcare Stocks Based On David Dreman - 4/19/2020", "Ligand's Icagen Expands License Agreement With Roche - Quick Facts", "Validea's Top Five Healthcare Stocks Based On David Dreman - 3/15/2020", "Notable Monday Option Activity: EQIX, LGND, FB", "Health Care Sector Update for 02/27/2020: LIVN,GOOG,GOOGL,LGND,TDOC,ORMP", "Health Care Sector Update for 02/27/2020: LGND,TDOC,ORMP", "Ligand Pharma Boosts FY20 Outlook On Higher Material Sales - Quick Facts", "Validea's Top Five Healthcare Stocks Based On David Dreman - 2/16/2020", "Health Care Sector Update for 02/07/2020: LGND,ASRT,COLL,SLRX", "Ligand Pharmaceuticals is Now Oversold (LGND)", "Ligand Pharmaceuticals Inc (LGND) Q4 2019 Earnings Call Transcript", "Ligand Pharmaceuticals Inc Q4 adjusted earnings Beat Estimates", "Ligand Pharmaceuticals Q4 19 Earnings Conference Call At 4:30 PM ET", "This ETF Holds Stocks Insiders Want to Own", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 1/19/2020", "Look Under The Hood: PJP Has 11% Upside", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/15/2019", "Health Care Sector Update for 02/07/2020: LGND,ASRT,COLL,SLRX", "Ligand Pharmaceuticals Inc (LGND) Q3 2019 Earnings Call Transcript", "Ligand Pharma Updates Earnings Guidance - Quick Facts", "Ligand Pharmaceuticals Inc Q3 adjusted earnings Miss Estimates", "Ligand Pharmaceuticals Q3 19 Earnings Conference Call At 4:30 PM ET", "Notable Monday Option Activity: LCII, TNDM, LGND", "5 Top Healthcare ETFs", "Implied MDY Analyst Target Price: $387", "Notable Thursday Option Activity: FDX, LGND, BBBY", "3 Top Biotech Stocks to Buy in August", "Thursday 8/1 Insider Buying Report: LGND, TSLA", "5 Top Losers In Healthcare Sector (RMTI, LGND, MIST...)", "Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript", "Ligand Pharmaceuticals Inc Q2 adjusted earnings Beat Estimates", "Ligand Pharmaceuticals Q2 19 Earnings Conference Call At 9:00 AM ET", "Insiders Buy the Holdings of VHT ETF", "Notable Tuesday Option Activity: M, LGND, CMI", "Insiders Buy the Holdings of VTWO ETF", "XBI, LGND, SAGE, GBT: Large Inflows Detected at ETF", "Health Care Sector Update for 05/03/2019: MCK,LGND,XRAY,GMED", "Health Care Sector Update for 05/03/2019: LGND,XRAY,GMED", "Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript", "Notable ETF Inflow Detected - XBI, LGND, SAGE, GBT", "SPDR S&P 400 Mid Cap Growth ETF -- Insider Buying Index Registering 10.2%", "7 Stocks That Insiders Are Buying", "5 Top Biotech Stocks to Buy in 2019", "RXL's Holdings Could Mean 18% Gain Potential", "SPDR S&P Biotech ETF Experiences Big Outflow", "Notable ETF Outflow Detected - XBI, LGND, IMMU, NBIX", "Is Sage Therapeutics a Good Stock to Buy Now?", "Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight", "Rising P/E an Overlooked Criterion: 5 Top Stocks", "XBI, IONS, LGND, GBT: Large Outflows Detected at ETF", "LGND vs. ILMN: Which Stock Should Value Investors Buy Now?", "Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals", "4 High Earnings Yield Stocks to Strengthen Your Portfolio", "Ligand (LGND) Down 9.1% Since Last Earnings Report: Can It Rebound?", "Ligand Sells Promacta Rights for $827M, Updates '19 View", "Health Care Sector Update for 03/06/2019: HZNP,INFI,HCR,VSTM,SRPT,LGND,NVS", "Here's Why Ligand Pharmaceuticals Is Having a Bad Day", "Add Up The Pieces: RFG Could Be Worth $172", "Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT", "Wednesday's ETF Movers: XLB, XBI", "Wednesday Sector Laggards: Hospital & Medical Practitioners, Drugs", "Analysts Anticipate IYH Will Reach $217", "Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars", "Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?", "AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates", "Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT", "Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript", "Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales", "Ligand (LGND) Takes a Hit on Citron's Negative Research Report", "Here's Why Ligand Pharmaceuticals Plummeted 16% Today", "Ligand Pharmaceuticals Enters Oversold Territory (LGND)", "3 Top Healthcare Stocks to Buy Right now", "Implied RFG Analyst Target Price: $179", "Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View", "March 2019 Options Now Available For Ligand Pharmaceuticals (LGND)", "Notable Friday Option Activity: OFIX, BC, LGND", "10 Triple-A Stocks to Buy for the Rest of 2018", "Validea's Top Five Healthcare Stocks Based On John Neff - 11/18/2018", "Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.", "Implied RFG Analyst Target Price: $182", "Validea Peter Lynch Strategy Daily Upgrade Report - 11/10/2018", "Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report?", "Ligand Pharmaceuticals Enters Oversold Territory (LGND)", "Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript", "Ligand Pharmaceuticals (LGND) Tops Q3 Earnings and Revenue Estimates", "What Lies in Store for Ligand (LGND) This Earnings Season?", "3 Hammered Healthcare Stocks to Buy Now", "3 Top Biotech Stocks to Buy Right Now", "IJR, CACI, NSP, LGND: Large Inflows Detected at ETF", "Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View", "LGND Crosses Below Key Moving Average Level", "5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage", "IWM, LIVN, ETSY, LGND: ETF Outflow Alert", "Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know", "Implied IYH Analyst Target Price: $217", "Ligand Pharmaceuticals Enters Oversold Territory (LGND)", "iShares Russell 2000 ETF Experiences Big Inflow", "Ligand Pharmaceuticals (LGND) Gains But Lags Market: What You Should Know", "Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals", "VistaGen Up on Fast Track Designation to Pain Candidate", "5 Stocks With High Net Income Ratio to Scoop Up", "Alnylam Files Clinical Trial Application for ALN-AAT02 in UK", "Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo", "Medicines Company to Continue Inclisiran Studies as Planned", "Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara", "3 Top Mid-Cap Stocks to Buy Right Now", "Ultragenyx Reports Top-line Data From Gene Therapy Candidate", "Noteworthy ETF Inflows: IJR, LGND, TREX, CACI", "3 Biotech Stocks With Rising Estimates in the Past Month", "Best ETFs for 2018: Don\u2019t Sweat This Quarter for the SBIO ETF", "10 Triple-A Stocks to Buy for the Rest of 2018", "AMAG In-Licenses Global Rights to Orphan Drug Candidate", "Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks", "Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce", "Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate", "FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study", "FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program", "Alexion's Soliris Successful in Phase III Study for NMOSD", "Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx", "CHMP Reconfirms Negative Opinion for Sarepta's Exondys", "Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?", "Verastem Out-Licenses China Rights to Cancer Drug Copiktra", "Noteworthy ETF Inflows: IJR, LGND, TREX, NEOG", "Progenics Pharma's Stock Down on Dismal Phase III Study Data", "Is Viking Therapeutics the Best NASH Stock to Buy Now?", "7 Best Biotech Stocks for Investors Who Hate Risk", "Ultragenyx's Shares Surge More Than 80% in the Year So Far", "Dr. Reddy's (RDY) Presence in Generics Market Remains Strong", "Zacks.com highlights: Attunity, Helix Energy Solutions Group, Ligand Pharmaceuticals, Turtle Beach and SVB Financial Group", "FDA Confirms Positive Safety Profile of Acadia's Nuplazid", "Cytori's Chemotherapy Candidate Gets Orphan Drug Status", "Gilead Inks Gene Editing Collaboration Deal for HBV Infection", "Noteworthy ETF Inflows: IWM, LIVN, IDTI, LGND", "Endocyte Announces FDA's Acceptance of Trial Endpoint Change", "Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo", "Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod", "Looking for a Top Momentum Pick? Why Ligand Pharmaceuticals (LGND) is a Great Choice", "Enhance Your Gains With These 5 Best Profitable Stocks", "3 Top Biotech Stocks to Buy in September", "ProQR Up More Than 120% on Favorable Eye Disorder Study Data", "bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy", "Ligand (LGND) Up 4.6% Since Last Earnings Report: Can It Continue?", "Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?", "3 Monster Biotech Stocks in the Making", "Horizon Pharma Completes Enrollment in Eye Disease Study", "Top Ranked Momentum Stocks to Buy for September 7th", "iShares Core S&P Small-Cap ETF Experiences Big Outflow", "Vertex Inks Deal With Genomics to Make Serious Disease Drugs", "Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A", "Alnylam Gets European Nod for First-Ever RNAi Therapeutic", "Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data", "Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval", "Bayer's Blood Thinner Xarelto Fails in Line Extension Studies", "Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout", "Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema", "Alexion's BLA for ALXN1210 Gets Priority Review From FDA", "Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA", "Zacks.com featured highlights include: Ligand, Energy Recovery, Turtle Beach, Cleveland-Cliffs and SVB", "IJR, LGND, TREX, CACI: Large Inflows Detected at ETF", "Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?", "Pick These 5 Profitable Stocks With Impressive Returns", "Why Ligand (LGND) Could Be an Impressive Growth Stock", "Profit Keeps Piling Up for Ligand Pharmaceuticals", "Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech", "IJR, LGND, CACI, NEOG: Large Outflows Detected at ETF", "Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View", "After-Hours Earnings Report for August 6, 2018 : MAR, ANDV, ANSS, MOS, ANDX, Z, BWXT, WTW, HHC, RNG, ETSY, LGND", "iShares Core S&P Small-Cap ETF Experiences Big Inflow", "What Lies in Store for Ligand (LGND) This Earnings Season?", "Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 7/15/2018", "IJR, LGND, FCFS, ASGN: ETF Inflow Alert", "3 Top Biotech Stocks to Buy Right Now", "First Week of July 20th Options Trading For Ligand Pharmaceuticals (LGND)", "Validea Motley Fool Strategy Daily Upgrade Report - 6/29/2018", "IJR, LGND, FCFS, ASGN: ETF Inflow Alert", "The LGND Paradox: Analysts Bullish But Forecast -10.53% Fall", "Noteworthy ETF Inflows: IJR, LGND, FCFS, ASGN", "3 Biotech Stocks Up in the Past Month on Industry Turnaround", "Notable ETF Inflow Detected - IJT, STMP, LGND, HQY", "3 Biotech Stocks Up in the Past Month on Industry Turnaround", "The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals", "\"Right To Try\" Brings Good News for Biotech Sector: 5 Picks", "Validea Motley Fool Strategy Daily Upgrade Report - 6/1/2018", "Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up", "Noteworthy Wednesday Option Activity: FDC, LGND, TMUS", "5 Biotech Stocks to Boost Your Portfolio's Health This Year", "Catalyst's Fridapse Gets Priority Review by FDA, Shares Up", "Allergan Recalls Taytulla Oral Contraceptives, Stock Down", "Bayer's Generic Competition, Pipeline Setback Issues Remain", "Prothena Restructures Resources, to Cut Workforce by 57%", "AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint", "SWTUY or LGND: Which Is the Better Value Stock Right Now?", "5 Biotech Stocks to Boost Your Portfolio\u2019s Health This Year", "Allergan Stock Down Since Q1 Earnings Report: Here's Why", "Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y", "Inovio Initiates Phase II Study on Pipeline Drug VGX-3100", "AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia", "Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?", "AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down", "Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study", "Agios (AGIO) Progressing Well on Pipeline Amid Competition", "Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data", "Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study", "Roche's Actemra Gets FDA Nod for Subcutaneous Formulation", "Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline", "Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents", "Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down", "Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss", "Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion", "Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat", "Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses", "VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters", "Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down", "Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View", "Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings", "Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1", "Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up", "Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y", "AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected", "Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1", "Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected", "Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates", "Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View", "Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down", "Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View", "Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More", "Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss", "Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat", "Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View", "Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1", "Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress", "Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss", "Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View", "Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates", "Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y", "Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1", "Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO", "What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)", "Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1", "What Lies Ahead for Ligand (LGND) This Earnings Season?", "AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View", "Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss", "Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View", "Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook", "Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y", "Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?", "Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y", "Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1", "Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring", "Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark", "Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales", "Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat", "AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains", "Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up", "BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat", "Catalyst Enrolls First Patient in Phase III Firdapse Study", "Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong", "Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer", "Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline", "Bayer to Divest 3.6% Stake to Singapore Company Temasek", "Merck's Keytruda Betters Survival in Lung Cancer Combo Study", "Alnylam (ALNY) Reports Positive Data for RNAi Candidate", "Alkermes Rallies as FDA Accepts NDA for Depression Drug", "Intercept Reports Phase III Sub-Study Liver Biopsy Data", "Calithera's Kidney Cancer Candidate Gets Fast Track Status", "Verastem (VSTM) in Focus: Stock Moves 8% Higher", "FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy", "Zacks.com featured highlights include: Ligand, ArcelorMittal, 58.com, Ameresco and Mammoth Energy", "Karyopharm's Myeloma Candidate Gets Fast Track Designation", "FDA Prolongs Review Date for AbbVie Endometriosis Candidate", "First Week of November 16th Options Trading For Ligand Pharmaceuticals (LGND)", "5 Best Profitable Stocks Offering Amazing Returns", "Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why", "FDA Restricts Sale of Bayer's Essure Birth Control Device", "Ionis (IONS) Clinches Licensing Agreement with AstraZeneca", "Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis", "Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher", "FDA Okays Label Expansion of Pacira's Exparel's, Stock Up", "Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel", "Zacks.com highlights: Michael Kors Holdings, Ligand Pharmaceuticals, Tivity Health, NV5 Global and Louisiana-Pacific", "Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up", "Novo Nordisk Obtains Licence for Sickle Cell Disease Program", "Conatus' Emricasan Fails in Phase II Study, Shares Sink", "Explore Driehaus Strategy With These 5 Momentum Stocks", "LGND Crosses Above Average Analyst Target", "Catalyst (CPRX) Up on New Drug Application for Firdapse", "Bio-Path Leukemia Combo Study Shows Positive Early Data", "EMA Accepts Regeneron/Sanofi's application for Dupixent", "Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why", "Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU", "Alkermes Sinks as FDA Refuses Depression Drug Review", "Edge Therapeutics Loses Edge on Failure of Late-Stage Study", "Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease", "4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End", "Regeneron Collaborates With Alnylam to Develop NASH Treatment", "Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?", "Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label", "Novo Nordisk Poised on Strong Pipeline Amid Competition", "Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks", "Heron's Pain Candidate Meets Endpoint in Pivotal Studies", "Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal", "Regeneron Eylea Hits 24-Week Primary Endpoint in Study", "Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up", "Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss", "GlaxoSmithKline Initiates Phase III Combo Study on Benlysta", "Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress", "Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y", "Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4", "AbbVie's Uterine Fibroids Candidate Succeeds in Phase III", "Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up", "Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer", "Alexion (ALXN) Gains On Positive Date From Lead Candidate", "Aradigm Files MAA for Bronchiectasis Candidate in the EU", "Regeneron and Sanofi Announce Positive Data on Praluent", "Pfizer Gets FDA Panel Backing for New Indication for Xeljanz", "Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up", "Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss", "Corcept Plans Korlym Label Expansion, Pipeline in Progress", "Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "Bayer, BASF in Talks for Vegetable Seeds Business Sell-Off", "Thursday's ETF Movers: PJP, XME", "Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls", "Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink", "Validea Motley Fool Strategy Daily Upgrade Report - 3/6/2018", "Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss", "Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View", "Lilly, Boehringer to Expand Jardiance Heart Failure Program", "Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat", "Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y", "Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down", "Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y", "Pacira (PCRX) Posts Earnings in Q4, Revenues in Line", "Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress", "9 Stocks to Buy Instead of Bitcoin", "FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma", "AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues", "Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid", "What's in Store for Ligand (LGND) This Earnings Season?", "3 Biotech Stocks to Buy for 2018", "Omeros Shows Rising Price Performance With Jump To 81 RS Rating", "Regenxbio Clears Technical Benchmark, Hitting 80-Plus RS Rating", "La Jolla Pharmaceutical Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y", "Stocks Showing Rising Market Leadership: Supernus Pharmaceuticals Earns 81 RS Rating", "Regenxbio Earns Relative Strength Rating Upgrade; Hits Key Benchmark", "GW Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark", "Alder Biopharmaceuticals Shows Rising Price Performance With Jump To 85 RS Rating", "Aerie Pharmaceuticals Sees IBD RS Rating Improve To 74", "Stocks With Rising Relative Strength: La Jolla Pharmaceutical", "Stocks Showing Improved Relative Strength: Omeros", "Stocks To Watch: TG Therapeutics Sees Relative Strength Rating Jump To 92", "Stocks Showing Market Leadership: Array Biopharma Earns 96 RS Rating", "Stocks Flashing Renewed Technical Strength: Exelixis", "TG Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Agios Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90", "Stocks To Watch: Acorda Therapeutics Sees RS Rating Jump To 84", "IBD Rating Upgrades: Innoviva Shows Improved Technical Strength", "10 Stocks to Buy Instead of Bitcoin", "Stocks Showing Improved Relative Strength: Regenxbio", "5 Big Biotech Stocks To Buy In 2018", "Stocks Showing Market Leadership: Voyager Therapeutics Earns 91 RS Rating", "Stock Gains Vanish As Small Caps Reverse Lower", "Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform", "Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90", "Biogen Trying To Close In On Key Technical Measure", "Omeros Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks With Rising Relative Strength: Biogen", "Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92", "Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark", "Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90", "Stocks With Rising Relative Price Strength: Regenxbio", "Supernus Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating", "Portola Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark", "Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating", "PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating", "Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer", "18 Reasons I Like Biotech Stocks in 2018", "Stocks Generating Improved Relative Strength: Biogen", "PTC Therapeutics Shows Market Leadership With Jump To 84 RS Rating", "La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark", "Flexion Therapeutics Getting Closer To Key Technical Measure", "Avexis Joins Rank Of Stocks With RS Ratings Over 90", "Health Care Sector Update for 12/26/2017: LGND,IGC,INSY,ABBV", "GW Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark", "Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold", "Stocks With Rising Relative Strength: PTC Therapeutics", "3 Growth Stocks I'd Buy Right Now", "5 Top Biotech Stocks to Buy Now", "3 Stocks That Could Put Alibaba's Returns to Shame", "Supernus Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating", "Medicines Company to Sell Infectious Disease Unit to Melinta", "Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%", "Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA", "AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA", "3 Growth Stocks for the Long Term", "Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)", "AstraZeneca Files for Label Expansion of Tagrisso in Japan", "Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?", "Biogen Acquires Worldwide License for Alkermes' MS Candidate", "Spectrum Doubles in 3 Months: What's Driving the Rally?", "Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler", "Puma Inks License Deal to Commercialize Cancer Drug Nerlynx", "Lilly Inks Deal to Include Dexcom Products in Diabetes System", "Catalyst Initiates Phase II Study for Pipeline Drug Firdapse", "Valeant Closes Senior Note Offering, Reprices Term Loan", "Catalyst (CPRX) Reports Positive Phase III Data on Firdapse", "Can Valeant (VRX) Turn Around on Rebuilding Initiatives?", "Stocks Flashing Renewed Technical Strength: Intra-Cellular Therapies", "Roche Reports Positive Data From Tecentriq Combination Study", "Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?", "Agios Posts New Data on Glioma Candidate from Dose Expansion", "Supernus Pharmaceuticals Shows Rising Price Performance With Jump To 83 RS Rating", "Stocks With Rising Relative Price Strength: Zynerba Pharmaceuticals", "Alnylam's RNAi Candidate Gains Breakthrough Therapy Status", "IBD Rating Upgrades: Biogen Shows Improved Price Strength", "Acceleron Pharma Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Alnylam Starts Rolling NDA Submission for RNAi Candidate", "Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease", "Stocks Flashing Renewed Technical Strength: Regenxbio", "Ionis Pharmaceuticals Shows Market Leadership With Jump To 81 RS Rating", "Stocks To Watch: Flexion Therapeutics Sees RS Rating Jump To 83", "Exelixis Clears Technical Benchmark, Hitting 80-Plus RS Rating", "IBD Rating Upgrades: Biogen Shows Improved Price Strength", "Acceleron Pharma Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Alnylam Starts Rolling NDA Submission for RNAi Candidate", "Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease", "Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis", "Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin", "Valeant (VRX) Announces Pricing of Senior Secured Notes", "Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee", "LGND Crosses Above Average Analyst Target", "Vertex Gets CHMP Recommendation for Orkambi Label Expansion", "Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak", "BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates", "Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised", "Omeros Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss", "Stocks To Watch: Intra-Cellular Therapies Sees RS Rating Rise To 88", "Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up", "Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up", "Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates", "Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3", "Puma Biotechnology Flops Despite Topping Sales, Loss Expectations", "Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss", "Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss", "Stocks To Watch: Intra-Cellular Therapies Sees RS Rating Rise To 88", "Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up", "Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up", "Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates", "Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3", "Puma Biotechnology Flops Despite Topping Sales, Loss Expectations", "Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss", "Stocks With Rising Relative Price Strength: Achaogen", "After-Hours Earnings Report for November 9, 2017 : DIS, NVDA, JWN, MSCC, NWSA, AL, PBYI, ICUI, AVXS, LGND, RBA, ESL", "Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3", "Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag", "Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines", "Flexion Therapeutics Getting Closer To Key Technical Measure", "PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y", "Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus", "Strange: Bullish LGND Analysts Actually See -1.3% Downside", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session", "Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating", "Exelixis Scores Relative Strength Rating Upgrade", "Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised", "Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y", "AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook", "Strange: Bullish LGND Analysts Actually See -1.3% Downside", "Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session", "Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating", "Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y", "Novartis Buys French Radiopharmaceutical Company", "Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3", "Sarepta Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating", "Stocks Flashing Renewed Technical Strength: Adamas Pharmaceuticals", "Intra-Cellular Therapies Earns Relative Strength Rating Upgrade", "IBD Rating Upgrades: Seattle Genetics Flashes Improved Price Strength", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 82", "La Jolla Pharmaceutical Earns Relative Strength Rating Upgrade", "Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View", "Biogen Sees Relative Strength Rating Climb To 75", "Sarepta Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating", "Adamas Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up", "3 Small, Profitable Biotechs With Fantastic Growth", "Aimmune Therapeutics Scores Relative Strength Rating Upgrade", "Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics", "Innoviva Clears Key Benchmark, Hitting 80-Plus RS Rating", "Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y", "Novartis Reports Positive Results on Thrombocytopenia Drug", "Impax Laboratories and Amneal Pharmaceuticals Agree to Merge", "Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals", "Inovio Initiates Bladder Cancer Study With Roche's Tecentriq", "Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks", "Stocks Showing Market Leadership: PTC Therapeutics Earns 92 RS Rating", "Exelixis Earns Relative Strength Rating Upgrade", "Gilead Sciences Shows Rising Relative Price Performance; Still Shy Of Key Threshold", "AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge", "Intra-Cellular Therapies Shows Rising Price Performance With Jump To 83 RS Rating", "Stocks With Rising Relative Price Strength: Ionis Pharmaceuticals", "Aerie Pharmaceuticals Scores Relative Strength Rating Upgrade", "Stocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating", "Forget Teva (TEVA), Buy These 5 Drug Stocks Instead", "Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating", "Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating", "Flexion Therapeutics Hits 80-Plus Relative Strength Rating Benchmark", "Stocks With Rising Relative Price Strength: Innoviva", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92", "Ligand (LGND) Signs Deal to Acquire Crystal Bioscience", "Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session", "Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher", "Stocks With Rising Relative Strength: Amgen", "Stocks Showing Improving Market Leadership: Intra-Cellular Therapies Earns 83 RS Rating", "Global Blood Therapeutic Earns Relative Strength Rating Upgrade", "Stocks With Rising Relative Strength: Intra-Cellular Therapies", "LGND Crosses Above Average Analyst Target", "Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher", "MannKind (MNKD) in Focus: Stock Moves 7.8% Higher", "Ionis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Stocks With Rising Relative Price Strength: Innoviva", "Aerie Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold", "Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating", "Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating", "Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Stocks Flashing Renewed Technical Strength: Acceleron Pharma", "Flexion Therapeutics Sees Relative Strength Rating Improve To 75", "Ionis Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day", "Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73", "Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating", "Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating", "Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Stocks Flashing Renewed Technical Strength: Acceleron Pharma", "Flexion Therapeutics Sees Relative Strength Rating Improve To 75", "Ionis Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day", "Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73", "Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session", "Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher", "3 Stocks With Nike-Like Return Potential", "Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day", "3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks", "Glaxo's Shingles Candidate Gets Positive FDA Committee Vote", "Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable", "Bull of the Day: Ligand Pharma (LGND)", "Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth", "Alnylam Shares Plunge on Patient Death, Dosing Suspended", "Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.", "Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%", "Can Ligand's Captisol Deals Boost Growth in the Long Run?", "RK Capital Management, LLC Buys Electronics for Imaging Inc, Douglas Dynamics Inc, KBR Inc, ...", "4 Biotech Stocks to Improve Your Portfolio's Health", "Can Ligand (LGND) Pull a Surprise This Earnings Season?", "Invest Like \"Royalty\" With These 3 Stocks", "Ligand Signs Agreement with Amgen, Grants Rights to Captisol", "3 Hot Stocks to Buy in July", "Ligand Gets Milestone Payment on Partner Drug FDA Approval", "Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?", "Key FDA Events to Watch Out for in Jun 2017", "Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised", "Can Ligand (LGND) Pull a Surprise This Earnings Season?", "Invest Like \"Royalty\" With These 3 Stocks", "Ligand Signs Agreement with Amgen, Grants Rights to Captisol", "3 Hot Stocks to Buy in July", "Notable Tuesday Option Activity: IAC, LGND, WATT", "LGND Makes Bullish Cross Above Critical Moving Average", "3 Stocks With Apple-Like Return Potential", "Ligand (LGND) Signs Licensing Deal with xCella Biosciences", "These 3 Stocks Look Expensive but Are Actually Cheap", "Here's Why Organovo Holdings Stock Fell 5.2% In April", "Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates", "Can Ligand (LGND) Spring a Surprise this Earnings Season?", "Notable Tuesday Option Activity: IAC, LGND, WATT", "LGND Makes Bullish Cross Above Critical Moving Average", "3 Stocks With Apple-Like Return Potential", "Ligand (LGND) Signs Licensing Deal with xCella Biosciences", "These 3 Stocks Look Expensive but Are Actually Cheap", "Here's Why Organovo Holdings Stock Fell 5.2% In April", "Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates", "Can Ligand (LGND) Spring a Surprise this Earnings Season?", "Notable Tuesday Option Activity: IAC, LGND, WATT", "LGND Makes Bullish Cross Above Critical Moving Average", "Notable Wednesday Option Activity: RGR, RAD, LGND", "4 Biotech Stocks to Buy in January", "Ligand (LGND) Signs Licensing Deals with Ono and Novartis", "Health Care Sector Update for 12/22/2016: LGND", "Why Ligand Pharmaceuticals (LGND) Stock Might be a Great Pick", "Notable Wednesday Option Activity: LGND, TER, OSTK", "3 Top Growth Stocks to Buy in 2017", "3 Biotech Stocks I'd Buy Right Now", "Ligand's Partner Retrophin Provides New Data on Sparsentan", "3 Top Healthcare Stocks to Own If Donald Trump Becomes President", "Ligand Pharmaceuticals is Now Oversold (LGND)", "Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?", "Ligand Partner Melinta Therapeutics Submits NDA for Baxdela", "New Strong Sell Stocks for October 5th", "3 Top Biotech Stocks to Buy in October", "The Best Healthcare Stocks for 2017", "Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III", "Kite Pharma Reports Favorable Data from Lymphoma Study", "Analysts Forecast 14% Upside For IYH", "GW Pharma Attains 52-Week High on Positive Epidiolex Data", "Ligand Pharmaceuticals Enters Oversold Territory (LGND)", "Here's Why Ligand Pharmaceuticals Inc Is Plunging Today", "Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps", "Is It Too Late to Get In on This Millionaire-Maker Stock?", "Regeneron, Sanofi Skin Disease Drug Under Priority Review", "Ligand Inks CNS License Agreement with Seelos Therapeutics", "Teva Reports Positive Phase III Tardive Dyskinesia Data", "Health Care Sector Update for 09/22/2016: LGND,AVXL,BLUE", "Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology", "Novartis Reports Positive Phase II Data on Migraine Drug", "Epizyme Receives Milestone from Glaxo for Lymphoma Drug", "3 Top Biotech Stocks to Buy on Sale", "Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials", "Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval", "Ligand (LGND) Commences Phase II Type II Diabetes Study", "5 Biotech Stocks That Are Broker Favorites", "4 Top Stocks on Track to Double Their Sales and Profits by 2019", "Ligand/Retrophin Rare Disease Drug Positive in Phase II", "Why Shares of Retrophin Inc Are Soaring Today", "Commit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options", "These 3 Stocks Are Up Over 700% in the Last 5 Years", "Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?", "Ligand Pharmaceuticals (LGND) Shares Cross Below 200 DMA", "We Did The Math PTH Can Go To $54", "4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer", "Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks", "5 Stocks to Play Momentum the Driehaus Way", "LGND Makes Bullish Cross Above Critical Moving Average", "Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)", "Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July", "Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View", "Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y", "Ligand (LGND) Q2 Earnings: What's in Store for the Stock?", "Ligand Pharmaceuticals Reaches Analyst Target Price", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%", "Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top", "The 3 Most Unbelievably Undervalued Healthcare Stocks", "Here's Why SAGE Therapeutics Inc. Is Surging Today", "Ligand (LGND) Signs Deal with Gilead for OmniAb Technology", "3 Biotech Stocks to Buy on Sale Right Now", "3 Healthcare Stocks That Are Looking Cheap", "7 Profitable Medical Stocks Ranked as Buys Now", "7 Biotech Stocks that are Buys Right Now", "3 Biotech Stocks for Conservative Investors", "3 Incredibly Cheap Biotech Stocks", "Analysts See 12% Gains Ahead For The Holdings of PWC", "3 Growth Stocks to Buy in June", "3 Highly Rated IBD Stocks Powering A Top Biotech ETF\u2019s Revival", "Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View", "Ligand (LGND) Beats Q1 Earnings and Revenue Estimates", "Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More", "Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead", "Ligand Pharma Adds Tech, Grows On Partners' Success", "Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher?", "Analysts Anticipate 10% Gains Ahead For The Holdings of EZM", "5 Growth Stocks to Buy in March", "Bullish Two Hundred Day Moving Average Cross - LGND", "Small-Cap ETFs Stride Ahead As Investors Turn Optimistic On Oil, GDP", "Bristol-Myers Inks Immuno-Oncology Deal with Dana-Farber", "Ligand (LGND) Q1 Earnings: What's in Store for the Stock?", "Merck (MRK) Gets CRL for Zetia & Vytorin sNDA from FDA", "Clovis' (CLVS) Rociletinib to Face FDA Advisory Panel in April", "Eli Lilly's Alimta Gets Negative Ruling in UK Patent Lawsuit", "Alnylam (ALNY) Reports Wider Q4 Loss; Revenues Miss", "Incyte (INCY) Beats on Q4 Earnings and Revenue Estimates", "Ligand (LGND) Beats on Q4 Earnings, Raises 2016 Outlook", "Alkermes' ALKS 3831 in 2nd Phase III Study for Schizophrenia", "Gilead's HCV Drug Harvoni Approved in Two More Indications", "Actelion (ALIOF) Misses Q4 Earnings, Revenue Estimates", "Cytori Tanks on Unfavorable Data from Osteoarthritis Study", "Epizyme's Tazemetostat Gets Orphan Drug Status in the U.S.", "Cempra Reports Positive Data on Antibiotic Solithromycin", "Ligand Pharmaceuticals (LGND): Q4 Earnings Preview", "Vertex (VRTX) Down on CRL for Kalydeco Label Expansion", "Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA", "INSYS (INSY) Initiates Phase II Study for Infantile Spasms", "Actelion (ALIOF) Misses Q4 Earnings, Revenue Estimates", "Cytori Tanks on Unfavorable Data from Osteoarthritis Study", "Epizyme's Tazemetostat Gets Orphan Drug Status in the U.S.", "Cempra Reports Positive Data on Antibiotic Solithromycin", "Ligand Pharmaceuticals (LGND): Q4 Earnings Preview", "Vertex (VRTX) Down on CRL for Kalydeco Label Expansion", "Spectrum (SPPI) Initiates Phase III Study on SPI-2012", "ImmunoGen/Merck Collaborate for Ovarian Cancer Study", "Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies", "LGND Makes Notable Cross Below Critical Moving Average", "Synthetic Biologics Tanks on Unfavorable Trimesta Data", "First Week of March 18th Options Trading For Ligand Pharmaceuticals (LGND)", "Avalanche (AAVL) Set to Acquire Annapurna Therapeutics", "Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study", "Spectrum (SPPI) Initiates Phase III Study on SPI-2012", "ImmunoGen/Merck Collaborate for Ovarian Cancer Study", "Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies", "LGND Makes Notable Cross Below Critical Moving Average", "MannKind (MNKD) Signs Deal with Receptor Life Sciences", "Alkermes Hit 52-Week Low on Unfavorable Phase III Data", "Cymabay Gives Update on Phase III Program on Arhalofenate", "Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis", "SurModics Buys NorMedix for $14M, Adjusts 2016 Outlook", "Impax's Emverm Approved for Parasitic Worm Infestations", "BioMarin's DMD Drug Kyndrisa Receives CRL from the FDA", "Ligand, Emergent BioSolutions Tie Up for OmniAb Technology", "Esperion (ESPR) Initiates Phase III Study for Hyperlipidemia", "Alnylam Provides Update on RNAi Therapeutics Pipeline", "Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus", "Orexigen Targets Profitability by 2018, Focus on Contrave", "SurModics Buys NorMedix for $14M, Adjusts 2016 Outlook", "Impax's Emverm Approved for Parasitic Worm Infestations", "The Best Value Stocks of 2015", "15 Best Stocks to Ring Out the Old, Ring In the New", "Ligand (LGND) Upgraded to Buy, Perfect for Your Portfolio", "The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis", "5 Biotech Stocks That Doubled in 2015", "Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis", "Bristol-Myers' Opdivo/Yervoy sBLA to Face Final Decision", "BioMarin Reveals Interim Data from Pompe Disease Study", "What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?", "Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.", "Here's Why Spectrum Pharmaceuticals' Stock Plunged Today", "Ligand, SAGE Captisol Partnership to Also Include SAGE-689", "The Fastest-Growing Biotech Stocks", "Novartis' (NVS) Promacta Label Further Expanded in U.S.", "Relative Strength Alert For Ligand Pharmaceuticals", "Ligand (LGND) Beats on Q3 Earnings, Lowers 2015 Outlook", "Collegium's Xtampza to be Reviewed by FDA Advisory Panels - Analyst Blog", "Synta's Q2 Loss Narrower than Expected, Focus on Pipeline - Analyst Blog", "Mylan Beats on Q2 Earnings, Revenues In Line, Guidance Up - Analyst Blog", "Dan Loeb Sees Opportunity in Latest Target Baxter International", "Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog", "SurModics (SRDX) Beats on Q3 Earnings, Improves Outlook - Analyst Blog", "Perrigo Beats on Q2 Earnings, Revenues In Line, Keeps View - Analyst Blog", "Endo Beats on Q2 Earnings and Revenues, Maintains View - Analyst Blog", "Mallinckrodt Beats Q3 Earnings, Transformation in Progress - Analyst Blog", "Zoetis Beats on Q2 Earnings and Revenues, Narrows View - Analyst Blog", "Regeneron Beats on Q2 Earnings, Eylea 2015 View Upped - Analyst Blog", "BioMarin Q2 Loss Narrower than Expected, Maintains Outlook - Analyst Blog", "Will Ligand Pharmaceuticals (LGND) Beat Earnings in Q2? - Analyst Blog", "QLT (QLTI) Reports Wider-than-Expected Loss in Q2 - Analyst Blog", "VIVUS (VVUS) Q2 Loss Narrower, Restructuring Announced - Analyst Blog", "Ligand Pharmaceuticals Beats on Q2 Earnings, Affirms View - Analyst Blog", "Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog", "Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog", "Bayer (BAYRY) Q2 Revenues Up Y/Y, 2015 Guidance Revised - Analyst Blog", "Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - Analyst Blog", "Theravance's Q2 Loss Wider-than-Expected, Revenues Miss - Analyst Blog", "Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog", "United Therapeutics Misses on Q2 Earnings & Revenues - Analyst Blog", "Amgen Beats on Q2 Earnings & Revenues, Raises Outlook - Analyst Blog", "Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog", "Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog", "Bayer (BAYRY) Q2 Revenues Up Y/Y, 2015 Guidance Revised - Analyst Blog", "Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog", "AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog", "XOMA Crashes after Gevokizumab Misses Primary Endpoint - Analyst Blog", "Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog", "Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog", "Hospira (HSP) Beats on Q2 Earnings Driven by Strong Sales - Analyst Blog", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "Commit To Purchase Ligand Pharmaceuticals At $75, Earn 6.7% Annualized Using Options", "Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog", "Bristol-Myers Inks Another Fibrotic Disease Agreement - Analyst Blog", "Why Ligand Pharmaceuticals (LGND) Could Be an Impressive Growth Stock - Tale of the Tape", "Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog", "Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog", "Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog", "Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog", "Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog", "Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog", "Bristol-Myers Inks Another Fibrotic Disease Agreement - Analyst Blog", "Why Ligand Pharmaceuticals (LGND) Could Be an Impressive Growth Stock - Tale of the Tape", "Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog", "Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog", "Qiagen's EGFR Test Gets PMA Nod to Treat Lung Cancer - Analyst Blog", "3 Biotech Stocks That Could Grow Faster than Apple", "Why Ligand Pharmaceuticals (LGND) Could Be Positioned for a Surge? - Tale of the Tape", "Health Care Sector Update for 06/12/2015: CRBP, LGND, PRTA", "Ligand Pharmaceuticals Reports Type II Diabetes Drug Data - Analyst Blog", "Ligand Pharmaceuticals Updates Viking IPO, Ups 2015 View - Analyst Blog", "Aratana's (PETX) Pain Drug for Dogs Effective in Pivotal Study - Analyst Blog", "3 Best of Breed Biotech Stocks", "Interesting LGND Put And Call Options For June 19th", "Health Care Sector Update for 04/20/2015: CLDX, LGND, LLY", "It's \"hip\" to be repaired: Viking Therapeutics refiles terms for $20 million IPO", "3 Up and Coming Biotech Stocks to Watch", "Ligand Pharmaceuticals: Biotech's Jack Of All Trades", "Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog", "US IPO Weekly Recap: 4 IPOs offer dividends and drugs", "Notable Two Hundred Day Moving Average Cross - LGND", "Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape", "Glaxo Submits Another Revolade Application in the EU - Analyst Blog", "Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog", "Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND", "Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog", "Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape", "Sector Update: Health Care", "Ligand (LGND) Shares March Higher, Can It Continue? - Tale of the Tape", "Why Earnings Season Could Be Great for Ligand (LGND) - Tale of the Tape", "Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog", "Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog", "Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates? - Analyst Blog", "Will Amgen (AMGN) Disappoint in the Q3 Earnings Season? - Analyst Blog", "Sector Update: Health-Care Shares Flat Before Opening Bell", "Sector Update: Health Care", "Ligand (LGND) Shares March Higher, Can It Continue? - Tale of the Tape", "Why Earnings Season Could Be Great for Ligand (LGND) - Tale of the Tape", "Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog", "Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog", "Will Ligand Pharmaceuticals Beat Q3 Earnings Estimates? - Analyst Blog", "Amgen Gains as Third Point Suggests Split - Analyst Blog", "Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog", "Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog", "Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog", "Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog", "Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog", "Will Bristol-Myers (BMY) Disappoint This Earnings Season? - Analyst Blog", "Will Agenus (AGEN) Incur Wider-than-Expected Q3 Loss? - Analyst Blog", "Amgen Gains as Third Point Suggests Split - Analyst Blog", "Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog", "Why Ligand Pharmaceuticals (LGND) Isn't Done Growing Earnings Yet - Tale of the Tape", "Pacific Biosciences to Incur Narrower-than-Expected Q3 Loss - Analyst Blog", "Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog", "Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? - Analyst Blog", "Celgene (CELG) Q3 Earnings to Be Overrun by Expenses? - Analyst Blog", "Will Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? - Analyst Blog", "Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? - Analyst Blog", "Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog", "Will Abbott Labs (ABT) Miss on Earnings This Quarter? - Analyst Blog", "GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog", "Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition - Analyst Blog", "AbbVie Reconsiders Shire Acquisition Due to New Tax Rules - Analyst Blog", "Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog", "NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% - Tale of the Tape", "Cyclacel Provides SEAMLESS Study Update on Sapacitabine - Analyst Blog", "Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog", "Will Ligand Pharmaceuticals (LGND) Crush Estimates at Its Next Earnings Report? - Tale of the Tape", "Will Johnson & Johnson Beat Earnings on Pharma Sales? - Analyst Blog", "Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Tape", "Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog", "Prosensa Starts Rolling NDA Submission for Drisapersen - Analyst Blog", "Targacept's Nine-Year Association with AstraZeneca to End - Analyst Blog", "AbbVie's Humira Positive in Late-Stage Skin Disease Study - Analyst Blog", "Pfizer's Breast Cancer Candidate Gets Priority Review - Analyst Blog", "Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog", "Will Johnson & Johnson Beat Earnings on Pharma Sales? - Analyst Blog", "Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Tape", "Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog", "Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues - Analyst Blog", "AstraZeneca's Benralizumab Encourages in Phase II Study - Analyst Blog", "XOMA Starts Phase I Study on XOMA 358 for Hyperinsulinism - Analyst Blog", "Ligand Provides Better-than-Expected Q3 Earnings Guidance - Analyst Blog", "Amgen Up on Positive Phase III Data on Psoriasis Biosimilar - Analyst Blog", "Dow Surges Over 200 Points After FOMC Minutes; Blackhawk Shares Jump On Strong Results", "Interface Drops On Q3 Warning; Symantec Shares Rise", "Diabetes biotech Viking Therapeutics sets terms for $55 million IPO", "Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog", "AbbVie's Humira Label Expanded in U.S. - Analyst Blog", "Insiders Now Seeing Red With LGND At New 52-Week Low", "Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog", "Commit To Purchase Ligand Pharmaceuticals At $40, Earn 21.8% Annualized Using Options", "NASDAQ Biotechnology Top Performers (As Of Market Open September 11)", "Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog", "Diabetes biotech Viking Therapeutics sets terms for $55 million IPO", "Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog", "AbbVie's Humira Label Expanded in U.S. - Analyst Blog", "Ligand Pharmaceuticals (LGND) Jumps: Stock Up 10.1% - Tale of the Tape", "Glaxo's Promacta in Phase III for MDS - Analyst Blog", "Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog", "Interesting LGND Put And Call Options For November 22nd", "Glaxo's Promacta Holds Promise - Analyst Blog", "Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog", "Spectrum Pharma Candidate Gets Positive Data - Analyst Blog", "Milestone Payment for Ligand Pharma - Analyst Blog", "Bright Outlook at Ligand - Analyst Blog", "Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog", "Update on Ligand/Glaxo's Promacta - Analyst Blog", "Update on Glaxo's Portfolio - Analyst Blog", "Insiders at Chefs Warehouse Buy Shares While Ligand Pharmaceuticals Sees a Sale", "Ligand, CURx Collaborate - Analyst Blog", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5% - Tale of the Tape", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "Glaxo's Promacta Label Expanded - Analyst Blog", "Upcoming BioPharma Catalyst Trades to Consider", "The Medicines Co. Halts MDCO-2010 - Analyst Blog", "MDCO's Cangrelor Enrollment by 4Q - Analyst Blog", "Glaxo Aims to Expand Promacta Label - Analyst Blog", "Is the Stock Market Overheated? Here's my Plan...", "Ligand, Azure Collaborate - Analyst Blog", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "This Week in Biotech: More Treats than Tricks", "A Low-Risk Pick for my $100,000 Real-Money Portfolio"], "Elapsed Time": ["MAY 29, 2020", "MAY 14, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 6, 2020", "MAY 6, 2020", "APR 20, 2020", "APR 19, 2020", "MAY 29, 2020", "MAR 15, 2020", "MAR 9, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 16, 2020", "FEB 7, 2020", "MAR 16, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "JAN 19, 2020", "JAN 2, 2020", "DEC 15, 2019", "FEB 7, 2020", "NOV 6, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 4, 2019", "OCT 26, 2019", "SEP 23, 2019", "NOV 14, 2019", "AUG 14, 2019", "AUG 1, 2019", "JUL 31, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 26, 2019", "SEP 10, 2019", "JUN 6, 2019", "MAY 10, 2019", "MAY 3, 2019", "MAY 3, 2019", "MAY 2, 2019", "MAY 2, 2019", "APR 25, 2019", "JUN 25, 2019", "APR 19, 2019", "APR 18, 2019", "APR 16, 2019", "MAR 27, 2019", "MAR 20, 2019", "MAR 19, 2019", "MAR 18, 2019", "APR 24, 2019", "MAR 15, 2019", "MAR 13, 2019", "MAR 12, 2019", "MAR 9, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 18, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 6, 2019", "FEB 14, 2019", "FEB 13, 2019", "FEB 11, 2019", "FEB 8, 2019", "MAR 6, 2019", "FEB 7, 2019", "FEB 6, 2019", "JAN 17, 2019", "JAN 16, 2019", "JAN 16, 2019", "DEC 22, 2018", "DEC 14, 2018", "FEB 8, 2019", "DEC 7, 2018", "DEC 7, 2018", "NOV 21, 2018", "NOV 18, 2018", "NOV 14, 2018", "NOV 13, 2018", "NOV 10, 2018", "DEC 8, 2018", "NOV 9, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 6, 2018", "NOV 1, 2018", "OCT 30, 2018", "OCT 25, 2018", "NOV 9, 2018", "OCT 18, 2018", "OCT 17, 2018", "OCT 16, 2018", "OCT 12, 2018", "OCT 11, 2018", "OCT 9, 2018", "OCT 8, 2018", "OCT 25, 2018", "OCT 5, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 3, 2018", "OCT 3, 2018", "OCT 3, 2018", "OCT 6, 2018", "SEP 28, 2018", "SEP 28, 2018", "SEP 28, 2018", "SEP 28, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 27, 2018", "OCT 1, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 25, 2018", "SEP 24, 2018", "SEP 24, 2018", "SEP 21, 2018", "SEP 26, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 21, 2018", "SEP 18, 2018", "SEP 13, 2018", "SEP 12, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 10, 2018", "SEP 7, 2018", "SEP 18, 2018", "SEP 7, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 7, 2018", "SEP 4, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 30, 2018", "AUG 28, 2018", "AUG 28, 2018", "SEP 5, 2018", "AUG 24, 2018", "AUG 21, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 27, 2018", "AUG 14, 2018", "AUG 13, 2018", "AUG 8, 2018", "AUG 7, 2018", "AUG 6, 2018", "JUL 31, 2018", "JUL 31, 2018", "AUG 16, 2018", "JUL 15, 2018", "JUL 13, 2018", "JUL 13, 2018", "JUN 29, 2018", "JUN 29, 2018", "JUN 26, 2018", "JUN 25, 2018", "JUL 23, 2018", "JUN 15, 2018", "JUN 11, 2018", "JUN 5, 2018", "JUN 4, 2018", "JUN 1, 2018", "JUN 1, 2018", "JUN 1, 2018", "JUN 20, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 30, 2018", "MAY 29, 2018", "MAY 28, 2018", "MAY 25, 2018", "MAY 24, 2018", "MAY 31, 2018", "MAY 23, 2018", "MAY 23, 2018", "MAY 22, 2018", "MAY 21, 2018", "MAY 21, 2018", "MAY 18, 2018", "MAY 18, 2018", "MAY 24, 2018", "MAY 17, 2018", "MAY 16, 2018", "MAY 15, 2018", "MAY 15, 2018", "MAY 14, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 17, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 9, 2018", "MAY 11, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 9, 2018", "MAY 7, 2018", "MAY 7, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 8, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 2, 2018", "MAY 4, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 1, 2018", "APR 30, 2018", "APR 30, 2018", "APR 27, 2018", "APR 27, 2018", "MAY 2, 2018", "APR 27, 2018", "APR 27, 2018", "APR 27, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 20, 2018", "APR 27, 2018", "APR 19, 2018", "APR 18, 2018", "APR 18, 2018", "APR 17, 2018", "APR 17, 2018", "APR 17, 2018", "APR 16, 2018", "APR 19, 2018", "APR 13, 2018", "APR 12, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "APR 11, 2018", "APR 11, 2018", "APR 13, 2018", "APR 10, 2018", "APR 10, 2018", "APR 9, 2018", "APR 9, 2018", "APR 9, 2018", "APR 6, 2018", "APR 6, 2018", "APR 11, 2018", "APR 6, 2018", "APR 5, 2018", "APR 5, 2018", "APR 5, 2018", "APR 5, 2018", "APR 4, 2018", "APR 3, 2018", "APR 6, 2018", "APR 3, 2018", "APR 3, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 27, 2018", "MAR 22, 2018", "MAR 22, 2018", "APR 3, 2018", "MAR 21, 2018", "MAR 21, 2018", "MAR 20, 2018", "MAR 20, 2018", "MAR 20, 2018", "MAR 19, 2018", "MAR 16, 2018", "MAR 21, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 16, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 9, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 13, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 7, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 5, 2018", "MAR 5, 2018", "MAR 8, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 1, 2018", "MAR 5, 2018", "FEB 28, 2018", "FEB 22, 2018", "FEB 19, 2018", "JAN 29, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 26, 2018", "FEB 28, 2018", "JAN 26, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 26, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 23, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 16, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 18, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 11, 2018", "JAN 9, 2018", "JAN 4, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 3, 2018", "JAN 3, 2018", "DEC 29, 2017", "JAN 9, 2018", "DEC 26, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 10, 2017", "DEC 3, 2017", "NOV 30, 2017", "DEC 29, 2017", "NOV 30, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 28, 2017", "NOV 30, 2017", "NOV 28, 2017", "NOV 27, 2017", "NOV 23, 2017", "NOV 23, 2017", "NOV 22, 2017", "NOV 22, 2017", "NOV 22, 2017", "NOV 28, 2017", "NOV 21, 2017", "NOV 21, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 21, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 13, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 14, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 6, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 8, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 1, 2017", "OCT 31, 2017", "NOV 2, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 27, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 20, 2017", "OCT 20, 2017", "OCT 27, 2017", "OCT 19, 2017", "OCT 18, 2017", "OCT 18, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 20, 2017", "OCT 13, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 11, 2017", "OCT 9, 2017", "OCT 9, 2017", "OCT 16, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 4, 2017", "OCT 4, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 5, 2017", "OCT 3, 2017", "OCT 3, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 27, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 27, 2017", "OCT 3, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 23, 2017", "SEP 20, 2017", "SEP 19, 2017", "SEP 14, 2017", "SEP 12, 2017", "SEP 27, 2017", "SEP 8, 2017", "SEP 8, 2017", "AUG 25, 2017", "AUG 18, 2017", "AUG 15, 2017", "AUG 11, 2017", "SEP 5, 2017", "AUG 1, 2017", "JUL 18, 2017", "JUL 18, 2017", "JUL 10, 2017", "JUN 21, 2017", "JUN 13, 2017", "JUN 5, 2017", "AUG 8, 2017", "AUG 1, 2017", "JUL 18, 2017", "JUL 18, 2017", "MAY 4, 2017", "MAY 2, 2017", "APR 25, 2017", "APR 11, 2017", "MAY 31, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 4, 2017", "MAY 2, 2017", "APR 25, 2017", "APR 11, 2017", "MAY 31, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 4, 2017", "MAY 2, 2017", "APR 25, 2017", "JAN 18, 2017", "DEC 26, 2016", "DEC 23, 2016", "DEC 22, 2016", "DEC 16, 2016", "DEC 14, 2016", "DEC 14, 2016", "JAN 29, 2017", "NOV 22, 2016", "NOV 6, 2016", "NOV 3, 2016", "OCT 28, 2016", "OCT 25, 2016", "OCT 5, 2016", "OCT 2, 2016", "DEC 10, 2016", "SEP 28, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 30, 2016", "SEP 26, 2016", "SEP 23, 2016", "SEP 23, 2016", "SEP 22, 2016", "SEP 19, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 26, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 15, 2016", "AUG 23, 2016", "AUG 19, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 12, 2016", "AUG 11, 2016", "SEP 7, 2016", "AUG 9, 2016", "AUG 8, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 2, 2016", "JUL 21, 2016", "JUL 21, 2016", "AUG 9, 2016", "JUL 13, 2016", "JUL 12, 2016", "JUL 11, 2016", "JUN 29, 2016", "JUN 24, 2016", "JUN 21, 2016", "JUN 17, 2016", "JUL 17, 2016", "JUN 2, 2016", "JUN 1, 2016", "MAY 28, 2016", "MAY 27, 2016", "MAY 5, 2016", "MAY 4, 2016", "MAY 3, 2016", "JUN 8, 2016", "APR 29, 2016", "APR 8, 2016", "MAR 24, 2016", "MAR 19, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 17, 2016", "MAY 2, 2016", "FEB 16, 2016", "FEB 15, 2016", "FEB 15, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 11, 2016", "FEB 11, 2016", "FEB 17, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 8, 2016", "FEB 8, 2016", "FEB 8, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 8, 2016", "FEB 2, 2016", "FEB 1, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 1, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 3, 2016", "JAN 22, 2016", "JAN 22, 2016", "JAN 21, 2016", "JAN 20, 2016", "JAN 12, 2016", "JAN 19, 2016", "JAN 15, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 19, 2016", "JAN 3, 2016", "DEC 31, 2015", "DEC 30, 2015", "JAN 8, 2016", "JAN 7, 2016", "JAN 7, 2016", "JAN 4, 2016", "JAN 12, 2016", "NOV 5, 2015", "OCT 23, 2015", "OCT 23, 2015", "SEP 30, 2015", "SEP 21, 2015", "AUG 26, 2015", "AUG 24, 2015", "NOV 10, 2015", "AUG 10, 2015", "AUG 7, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 5, 2015", "AUG 10, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 3, 2015", "JUL 31, 2015", "JUL 31, 2015", "AUG 5, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 31, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 24, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 24, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 23, 2015", "JUL 23, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 21, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 23, 2015", "JUL 15, 2015", "JUL 14, 2015", "JUL 4, 2015", "JUN 25, 2015", "JUN 12, 2015", "JUN 8, 2015", "JUN 3, 2015", "JUL 15, 2015", "MAY 30, 2015", "APR 21, 2015", "APR 20, 2015", "APR 10, 2015", "MAR 29, 2015", "MAR 25, 2015", "MAR 10, 2015", "MAY 1, 2015", "FEB 24, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 6, 2015", "JAN 26, 2015", "DEC 29, 2014", "OCT 29, 2014", "MAR 3, 2015", "OCT 27, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 22, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 23, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 20, 2014", "OCT 20, 2014", "OCT 22, 2014", "OCT 20, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 16, 2014", "OCT 15, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 7, 2014", "OCT 7, 2014", "OCT 10, 2014", "OCT 10, 2014", "OCT 9, 2014", "OCT 9, 2014", "OCT 8, 2014", "OCT 8, 2014", "SEP 2, 2014", "AUG 18, 2014", "OCT 7, 2014", "OCT 7, 2014", "OCT 2, 2014", "SEP 22, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 2, 2014", "AUG 18, 2014", "OCT 7, 2014", "AUG 5, 2014", "JUN 26, 2014", "JUN 25, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "APR 24, 2014", "MAR 18, 2014", "MAR 12, 2014", "MAR 3, 2014", "FEB 5, 2014", "SEP 26, 2013", "SEP 26, 2013", "AUG 19, 2013", "NOV 27, 2013", "MAR 18, 2013", "NOV 20, 2012", "NOV 15, 2012", "OCT 8, 2012", "JUL 3, 2012", "JUN 1, 2012", "MAR 26, 2012", "JUL 23, 2013", "MAR 18, 2013", "NOV 1, 2009", "FEB 9, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/ligands-icagen-expands-license-agreement-with-roche-quick-facts-2020-05-29", "https://www.nasdaq.com/articles/lgnd-crosses-below-key-moving-average-level-2020-05-14", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-inva-csod-lgnd-2020-05-07", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-lgnd-q1-2020-earnings-call-transcript-2020-05-07", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-q1-adjusted-earnings-beat-estimates-2020-05-06", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-q1-20-earnings-conference-call-at-4%3A30-pm-et-2020-05-06", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-lgnd-opk-ksu-2020-04-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/ligands-icagen-expands-license-agreement-with-roche-quick-facts-2020-05-29", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-eqix-lgnd-fb-2020-03-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-27-2020%3A-livngooggoogllgndtdocormp-2020-02-27", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-27-2020%3A-lgndtdocormp-2020-02-27", "https://www.nasdaq.com/articles/ligand-pharma-boosts-fy20-outlook-on-higher-material-sales-quick-facts-2020-02-27", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-07-2020%3A-lgndasrtcollslrx-2020-02-07-0", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-is-now-oversold-lgnd-2020-03-16", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-lgnd-q4-2019-earnings-call-transcript-2020-02-07", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-q4-adjusted-earnings-beat-estimates-2020-02-06", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-q4-19-earnings-conference-call-at-4%3A30-pm-et-2020-02-06", "https://www.nasdaq.com/articles/this-etf-holds-stocks-insiders-want-to-own-2020-02-06", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/look-under-the-hood%3A-pjp-has-11-upside-2020-01-02", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-07-2020%3A-lgndasrtcollslrx-2020-02-07", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-lgnd-q3-2019-earnings-call-transcript-2019-11-06", "https://www.nasdaq.com/articles/ligand-pharma-updates-earnings-guidance-quick-facts-2019-11-05", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-q3-adjusted-earnings-miss-estimates-2019-11-05", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-q3-19-earnings-conference-call-at-4%3A30-pm-et-2019-11-05", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-lcii-tndm-lgnd-2019-11-04", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/implied-mdy-analyst-target-price%3A-%24387-2019-09-23", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-fdx-lgnd-bbby-2019-11-14", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-august-2019-08-14", "https://www.nasdaq.com/articles/thursday-8-1-insider-buying-report%3A-lgnd-tsla-2019-08-01", "https://www.nasdaq.com/articles/5-top-losers-in-healthcare-sector-rmti-lgnd-mist...-2019-07-31", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-incorporated-lgnd-q2-2019-earnings-call-transcript-2019-07-30", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-q2-adjusted-earnings-beat-estimates-2019-07-30", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-q2-19-earnings-conference-call-at-9%3A00-am-et-2019-07-30", "https://www.nasdaq.com/articles/insiders-buy-the-holdings-of-vht-etf-2019-07-26", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-m-lgnd-cmi-2019-09-10", "https://www.nasdaq.com/articles/insiders-buy-holdings-vtwo-etf-2019-06-06", "https://www.nasdaq.com/articles/xbi-lgnd-sage-gbt%3A-large-inflows-detected-etf-2019-05-10", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-03-2019%3A-mcklgndxraygmed-2019-05-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-03-2019%3A-lgndxraygmed-2019-05-03", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-incorporated-lgnd-q1-2019-earnings-call-transcript-2019-05-03", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-lgnd-sage-gbt-2019-05-02", "https://www.nasdaq.com/articles/spdr-sp-400-mid-cap-growth-etf-insider-buying-index-registering-102-2019-04-25", "https://www.nasdaq.com/articles/7-stocks-that-insiders-are-buying-2019-06-25", "https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-2019-2019-04-19", "https://www.nasdaq.com/articles/rxls-holdings-could-mean-18-gain-potential-2019-04-18", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2019-04-16", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xbi-lgnd-immu-nbix-2019-03-27", "https://www.nasdaq.com/articles/sage-therapeutics-good-stock-buy-now-2019-03-20", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-catabasis-ligand-key-carbonite-and-second-sight", "https://www.nasdaq.com/articles/rising-pe-overlooked-criterion-5-top-stocks-2019-03-18", "https://www.nasdaq.com/articles/xbi-ions-lgnd-gbt-large-outflows-detected-etf-2019-04-24", "https://www.nasdaq.com/articles/lgnd-vs.-ilmn%3A-which-stock-should-value-investors-buy-now-2019-03-15", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-sallie-mae-united-continental-celgene", "https://www.nasdaq.com/articles/4-high-earnings-yield-stocks-to-strengthen-your-portfolio-2019-03-12", "https://www.nasdaq.com/articles/ligand-lgnd-down-9.1-since-last-earnings-report%3A-can-it-rebound-2019-03-09", "https://www.nasdaq.com/articles/ligand-sells-promacta-rights-for-%24827m-updates-19-view-2019-03-06", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-hznpinfihcrvstmsrptlgndnvs-2019-03-06", "https://www.nasdaq.com/articles/heres-why-ligand-pharmaceuticals-having-bad-day-2019-03-06", "https://www.nasdaq.com/articles/add-pieces-rfg-could-be-worth-172-2019-03-18", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-lgndnvsinfihcrvstmsrpt-2019-03-06-0", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xlb-xbi-2019-03-06", "https://www.nasdaq.com/articles/wednesday-sector-laggards-hospital-medical-practitioners-drugs-2019-03-06", "https://www.nasdaq.com/articles/analysts-anticipate-iyh-will-reach-217-2019-02-14", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-impresses-in-q4-gilead-slumps-macrogenics-soars-2019-02", "https://www.nasdaq.com/articles/merrimack-mack-stock-up-year-to-date%3A-is-a-rebound-likely-2019-02-11", "https://www.nasdaq.com/articles/amag-q4-loss-narrower-than-expected-revenues-lag-estimates-2019-02-08", "https://www.nasdaq.com/articles/health-care-sector-update-03062019-lgndnvsinfihcrvstmsrpt-2019-03-06", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-lgnd-q4-2018-earnings-conference-call-transcript-2019-02-07", "https://www.nasdaq.com/articles/vertex-vrtx-q4-earnings-beat-on-solid-cf-products-sales-2019-02-06", "https://www.nasdaq.com/articles/ligand-lgnd-takes-a-hit-on-citrons-negative-research-report-2019-01-17", "https://www.nasdaq.com/articles/heres-why-ligand-pharmaceuticals-plummeted-16-today-2019-01-16", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-enters-oversold-territory-lgnd-2019-01-16", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-12-22", "https://www.nasdaq.com/articles/implied-rfg-analyst-target-price-179-2018-12-14", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q4-earnings-sales-raises-19-view-2019-02-08", "https://www.nasdaq.com/articles/march-2019-options-now-available-ligand-pharmaceuticals-lgnd-2018-12-07", "https://www.nasdaq.com/articles/notable-friday-option-activity-ofix-bc-lgnd-2018-12-07", "https://www.nasdaq.com/articles/10-triple-stocks-buy-rest-2018-2018-11-21", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-11182018-2018-11-18", "https://www.nasdaq.com/articles/better-nash-stock-madrigal-pharmaceuticals-inc-vs-viking-therapeutics-inc-2018-11-14", "https://www.nasdaq.com/articles/implied-rfg-analyst-target-price-182-2018-11-13", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-11102018-2018-11-10", "https://www.nasdaq.com/articles/why-is-ligand-lgnd-down-14.9-since-last-earnings-report-2018-12-08", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-enters-oversold-territory-lgnd-2018-11-09", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-inc-lgnd-q3-2018-earnings-conference-call-transcript-2018-11-08", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-tops-q3-earnings-and-revenue-estimates-2018-11-08", "https://www.nasdaq.com/articles/what-lies-in-store-for-ligand-lgnd-this-earnings-season-2018-11-06", "https://www.nasdaq.com/articles/3-hammered-healthcare-stocks-buy-now-2018-11-01", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-10-30", "https://www.nasdaq.com/articles/ijr-caci-nsp-lgnd-large-inflows-detected-etf-2018-10-25", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q3-earnings-revenues-raises-view-2018-11-09", "https://www.nasdaq.com/articles/lgnd-crosses-below-key-moving-average-level-2018-10-18", "https://www.nasdaq.com/articles/5-beaten-down-biotech-stocks-pick-wreckage-2018-10-17", "https://www.nasdaq.com/articles/iwm-livn-etsy-lgnd-etf-outflow-alert-2018-10-16", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-stock-sinks-as-market-gains%3A-what-you-should-know-2018-10-12", "https://www.nasdaq.com/articles/implied-iyh-analyst-target-price-217-2018-10-11", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-enters-oversold-territory-lgnd-2018-10-09", "https://www.nasdaq.com/articles/ishares-russell-2000-etf-experiences-big-inflow-2018-10-08", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-gains-but-lags-market%3A-what-you-should-know-2018-10-25", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-mcbc-holdings-newpark-resources-cigna-weight-watchers-international", "https://www.nasdaq.com/articles/vistagen-up-on-fast-track-designation-to-pain-candidate-2018-10-04", "https://www.nasdaq.com/articles/5-stocks-with-high-net-income-ratio-to-scoop-up-2018-10-04", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat02-in-uk-2018-10-04", "https://www.nasdaq.com/articles/amgen-gets-fda-nod-for-once-weekly-regimen-of-kyprolis-combo-2018-10-03", "https://www.nasdaq.com/articles/medicines-company-to-continue-inclisiran-studies-as-planned-2018-10-03", "https://www.nasdaq.com/articles/paratek-prtk-gets-fda-approval-for-nuzyra-and-seysara-2018-10-03", "https://www.nasdaq.com/articles/3-top-mid-cap-stocks-buy-right-now-2018-10-06", "https://www.nasdaq.com/articles/ultragenyx-reports-top-line-data-from-gene-therapy-candidate-2018-09-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ijr-lgnd-trex-caci-2018-09-28", "https://www.nasdaq.com/articles/3-biotech-stocks-with-rising-estimates-in-the-past-month-2018-09-28", "https://www.nasdaq.com/articles/best-etfs-2018-dont-sweat-quarter-sbio-etf-2018-09-28", "https://www.nasdaq.com/articles/10-triple-stocks-buy-rest-2018-2018-09-28", "https://www.nasdaq.com/articles/amag-in-licenses-global-rights-to-orphan-drug-candidate-2018-09-27", "https://www.nasdaq.com/articles/amarins-stock-soars-as-fish-oil-drug-lowers-heart-risks-2018-09-27", "https://www.nasdaq.com/articles/insmed-insm-wins-fda-nod-for-lung-disease-drug-arikayce-2018-10-01", "https://www.nasdaq.com/articles/arena-arna-posts-favorable-top-line-data-on-pain-candidate-2018-09-25", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-epizymes-lead-candidates-study-2018-09-25", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-sareptas-dmd-gene-therapy-program-2018-09-25", "https://www.nasdaq.com/articles/alexions-soliris-successful-in-phase-iii-study-for-nmosd-2018-09-25", "https://www.nasdaq.com/articles/exelixis-ipsen-receive-positive-chmp-opinion-for-cabometyx-2018-09-24", "https://www.nasdaq.com/articles/chmp-reconfirms-negative-opinion-for-sareptas-exondys-2018-09-24", "https://www.nasdaq.com/articles/is-ligand-pharmaceuticals-lgnd-stock-outpacing-its-medical-peers-this-year-2018-09-21", "https://www.nasdaq.com/articles/verastem-out-licenses-china-rights-to-cancer-drug-copiktra-2018-09-26", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ijr-lgnd-trex-neog-2018-09-20", "https://www.nasdaq.com/articles/progenics-pharmas-stock-down-on-dismal-phase-iii-study-data-2018-09-20", "https://www.nasdaq.com/articles/viking-therapeutics-best-nash-stock-buy-now-2018-09-20", "https://www.nasdaq.com/articles/7-best-biotech-stocks-investors-who-hate-risk-2018-09-20", "https://www.nasdaq.com/articles/ultragenyxs-shares-surge-more-than-80-in-the-year-so-far-2018-09-20", "https://www.nasdaq.com/articles/dr.-reddys-rdy-presence-in-generics-market-remains-strong-2018-09-19", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-attunity-helix-energy-solutions-group-ligand-pharmaceuticals-turtle", "https://www.nasdaq.com/articles/fda-confirms-positive-safety-profile-of-acadias-nuplazid-2018-09-21", "https://www.nasdaq.com/articles/cytoris-chemotherapy-candidate-gets-orphan-drug-status-2018-09-18", "https://www.nasdaq.com/articles/gilead-inks-gene-editing-collaboration-deal-for-hbv-infection-2018-09-13", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iwm-livn-idti-lgnd-2018-09-12", "https://www.nasdaq.com/articles/endocyte-announces-fdas-acceptance-of-trial-endpoint-change-2018-09-11", "https://www.nasdaq.com/articles/alkermes-expands-study-to-evaluate-alks-4230-keytruda-combo-2018-09-11", "https://www.nasdaq.com/articles/perrigos-otc-version-of-diarrhea-drug-imodium-gets-fda-nod-2018-09-10", "https://www.nasdaq.com/articles/looking-for-a-top-momentum-pick-why-ligand-pharmaceuticals-lgnd-is-a-great-choice-2018-09", "https://www.nasdaq.com/articles/enhance-your-gains-with-these-5-best-profitable-stocks-2018-09-18", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-september-2018-09-07", "https://www.nasdaq.com/articles/proqr-up-more-than-120-on-favorable-eye-disorder-study-data-2018-09-06", "https://www.nasdaq.com/articles/bluebird-blue-reports-updated-data-on-lenti-d-gene-therapy-2018-09-06", "https://www.nasdaq.com/articles/ligand-lgnd-up-4.6-since-last-earnings-report%3A-can-it-continue-2018-09-05", "https://www.nasdaq.com/articles/is-ligand-pharmaceuticals-lgnd-stock-outpacing-its-medical-peers-this-year-2018-09-05", "https://www.nasdaq.com/articles/3-monster-biotech-stocks-making-2018-09-05", "https://www.nasdaq.com/articles/horizon-pharma-completes-enrollment-in-eye-disease-study-2018-09-05", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-september-7th-2018-09-07", "https://www.nasdaq.com/articles/ishares-core-sp-small-cap-etf-experiences-big-outflow-2018-09-04", "https://www.nasdaq.com/articles/vertex-inks-deal-with-genomics-to-make-serious-disease-drugs-2018-08-31", "https://www.nasdaq.com/articles/bayers-bayry-jivi-gets-fda-approval-to-treat-hemophilia-a-2018-08-31", "https://www.nasdaq.com/articles/alnylam-gets-european-nod-for-first-ever-rnai-therapeutic-2018-08-31", "https://www.nasdaq.com/articles/ultragenyx-to-file-nda-for-lc-faod-candidate-on-existing-data-2018-08-30", "https://www.nasdaq.com/articles/ultragenyxs-rare-disease-drug-mepsevii-gets-eu-approval-2018-08-28", "https://www.nasdaq.com/articles/bayers-blood-thinner-xarelto-fails-in-line-extension-studies-2018-08-28", "https://www.nasdaq.com/articles/bayer-bayry-misses-on-q2-earnings-closes-monsanto-buyout-2018-09-05", "https://www.nasdaq.com/articles/shires-takhzyro-gets-fda-nod-for-hereditary-angioedema-2018-08-24", "https://www.nasdaq.com/articles/alexions-bla-for-alxn1210-gets-priority-review-from-fda-2018-08-21", "https://www.nasdaq.com/articles/evoke-pharma-evok-announces-fda-acceptance-of-gimoti-nda-2018-08-17", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-ligand-energy-recovery-turtle-beach-cleveland", "https://www.nasdaq.com/articles/ijr-lgnd-trex-caci-large-inflows-detected-etf-2018-08-16", "https://www.nasdaq.com/articles/is-ligand-pharmaceuticals-lgnd-stock-outpacing-its-medical-peers-this-year-2018-08-16", "https://www.nasdaq.com/articles/pick-these-5-profitable-stocks-impressive-returns-2018-08-16", "https://www.nasdaq.com/articles/why-ligand-lgnd-could-be-an-impressive-growth-stock-2018-08-27", "https://www.nasdaq.com/articles/profit-keeps-piling-ligand-pharmaceuticals-2018-08-14", "https://www.nasdaq.com/articles/ligand-lgnd-proposes-to-buy-u.k.s-drug-discovery-biotech-2018-08-13", "https://www.nasdaq.com/articles/ijr-lgnd-caci-neog-large-outflows-detected-etf-2018-08-08", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q2-earnings-revenues-raises-view-2018-08-07", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-6-2018-mar-andv-anss-mos-andx-z-bwxt-wtw-hhc-rng-etsy", "https://www.nasdaq.com/articles/ishares-core-sp-small-cap-etf-experiences-big-inflow-2018-07-31", "https://www.nasdaq.com/articles/what-lies-in-store-for-ligand-lgnd-this-earnings-season-2018-07-31", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-drug-gets-fda-nod-for-children-2018-08-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-motley-fool-7152018-2018-07-15", "https://www.nasdaq.com/articles/ijr-lgnd-fcfs-asgn-etf-inflow-alert-2018-07-13", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-07-13", "https://www.nasdaq.com/articles/first-week-july-20th-options-trading-ligand-pharmaceuticals-lgnd-2018-06-29", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-6292018-2018-06-29", "https://www.nasdaq.com/articles/ijr-lgnd-fcfs-asgn-etf-inflow-alert-2018-06-26", "https://www.nasdaq.com/articles/lgnd-paradox-analysts-bullish-forecast-1053-fall-2018-06-25", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ijr-lgnd-fcfs-asgn-2018-07-23", "https://www.nasdaq.com/articles/3-biotech-stocks-up-in-the-past-month-on-industry-turnaround-2018-06-15", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ijt-stmp-lgnd-hqy-2018-06-11", "https://www.nasdaq.com/articles/3-biotech-stocks-up-in-the-past-month-on-industry-turnaround-2018-06-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-illumina-athersys-eyepoint-pharmaceuticals-rhythm", "https://www.nasdaq.com/articles/right-try-brings-good-news-biotech-sector-5-picks-2018-06-01", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-612018-2018-06-01", "https://www.nasdaq.com/articles/kitov-ktov-gets-approval-from-fda-for-consensi-shares-up-2018-06-01", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-fdc-lgnd-tmus-2018-06-20", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31", "https://www.nasdaq.com/articles/catalysts-fridapse-gets-priority-review-by-fda-shares-up-2018-05-31", "https://www.nasdaq.com/articles/allergan-recalls-taytulla-oral-contraceptives-stock-down-2018-05-30", "https://www.nasdaq.com/articles/bayers-generic-competition-pipeline-setback-issues-remain-2018-05-29", "https://www.nasdaq.com/articles/prothena-restructures-resources-to-cut-workforce-by-57-2018-05-28", "https://www.nasdaq.com/articles/abbvies-imbruvicas-phase-iii-study-meets-primary-endpoint-2018-05-25", "https://www.nasdaq.com/articles/swtuy-or-lgnd%3A-which-is-the-better-value-stock-right-now-2018-05-24", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31-0", "https://www.nasdaq.com/articles/allergan-stock-down-since-q1-earnings-report%3A-heres-why-2018-05-23", "https://www.nasdaq.com/articles/dr.-reddys-rdy-q4-earnings-fall-revenues-decline-y-y-2018-05-23", "https://www.nasdaq.com/articles/inovio-initiates-phase-ii-study-on-pipeline-drug-vgx-3100-2018-05-22", "https://www.nasdaq.com/articles/astrazenecas-lokelma-gains-fda-nod-to-treat-hyperkalemia-2018-05-21", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-hits-a-52-week-high-can-the-run-continue-2018-05-21", "https://www.nasdaq.com/articles/astrazenecas-azn-q1-earnings-sales-miss-stock-down-2018-05-18", "https://www.nasdaq.com/articles/pfizers-epilepsy-drug-lyrica-succeeds-in-pediatric-study-2018-05-18", "https://www.nasdaq.com/articles/agios-agio-progressing-well-on-pipeline-amid-competition-2018-05-24", "https://www.nasdaq.com/articles/amgens-amgn-repatha-gains-eu-nod-to-include-outcomes-data-2018-05-17", "https://www.nasdaq.com/articles/sanofi-eczema-drug-dupixent-succeeds-in-adolescents-study-2018-05-16", "https://www.nasdaq.com/articles/roches-actemra-gets-fda-nod-for-subcutaneous-formulation-2018-05-15", "https://www.nasdaq.com/articles/eli-lilly-lly-to-buy-aurka-pharma-expand-cancer-pipeline-2018-05-15", "https://www.nasdaq.com/articles/novartis-multiple-sclerosis-drug-gets-fda-nod-for-adolescents-2018-05-14", "https://www.nasdaq.com/articles/geron-gern-q1-loss-narrows-y-y-revenues-fall-shares-down-2018-05-11", "https://www.nasdaq.com/articles/intrexon-xon-q1-loss-narrower-than-expected-revenues-miss-2018-05-11", "https://www.nasdaq.com/articles/zoetis-zts-inks-deal-to-acquire-abaxis-for-%242-billion-2018-05-17", "https://www.nasdaq.com/articles/keryx-kerx-loss-narrower-than-expected-in-q1-sales-beat-2018-05-11", "https://www.nasdaq.com/articles/catalyst-cprx-posts-in-line-q1-loss-pipeline-progresses-2018-05-10", "https://www.nasdaq.com/articles/vivus-vvus-q1-loss-narrower-than-expected-qsymia-falters-2018-05-10", "https://www.nasdaq.com/articles/puma-biotech-pbyi-q1-loss-narrows-sales-miss-stock-down-2018-05-10", "https://www.nasdaq.com/articles/valeant-vrx-rallies-earnings-beat-q1-raises-view-2018-05-10", "https://www.nasdaq.com/articles/xiaflex-sterile-injectables-drive-endos-endp-q1-earnings-2018-05-10", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/endocyte-ecyt-q1-loss-narrower-than-expected-shares-up-2018-05-11", "https://www.nasdaq.com/articles/theravance-biopharma-tbph-q1-loss-narrows-sales-up-y-y-2018-05-09", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q1-loss-wider-than-expected-2018-05-09", "https://www.nasdaq.com/articles/merrimack-mack-reports-wider-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q1-loss-wider-than-expected-2018-05-09", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q1-earnings-sales-top-estimates-2018-05-09", "https://www.nasdaq.com/articles/infinity-infi-incurs-in-line-loss-in-q1-maintains-view-2018-05-09", "https://www.nasdaq.com/articles/agenus-agen-q1-loss-wider-than-expected-shares-down-2018-05-08", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q1-earnings-revenues-keeps-view-2018-05-09", "https://www.nasdaq.com/articles/drug-biotech-q1-earnings-lineup-on-may-8%3A-jazz-arna-more-2018-05-07", "https://www.nasdaq.com/articles/agios-agio-q1-loss-wider-than-expected-revenues-miss-2018-05-07", "https://www.nasdaq.com/articles/aduro-adro-q1-loss-narrower-than-expected-revenues-beat-2018-05-04", "https://www.nasdaq.com/articles/emergent-ebs-misses-on-q1-earnings-retains-2018-view-2018-05-04", "https://www.nasdaq.com/articles/spectrum-sppi-earnings-and-sales-beat-estimates-in-q1-2018-05-04", "https://www.nasdaq.com/articles/sarepta-srpt-q1-loss-narrows-exondys-51-sales-impress-2018-05-04", "https://www.nasdaq.com/articles/alnylams-alny-q1-loss-wider-than-expected-sales-miss-2018-05-04", "https://www.nasdaq.com/articles/perrigo-prgo-misses-on-earnings-in-q1-reiterates-view-2018-05-08", "https://www.nasdaq.com/articles/conatus-cnat-q1-loss-in-line-revenues-beat-estimates-2018-05-03", "https://www.nasdaq.com/articles/acorda-acor-q1-earnings-miss-estimates-sales-down-y-y-2018-05-03", "https://www.nasdaq.com/articles/bayer-bayry-misses-earnings-and-revenue-estimates-in-q1-2018-05-03", "https://www.nasdaq.com/articles/achillion-achn-posts-wider-than-expected-q1-loss-names-ceo-2018-05-03", "https://www.nasdaq.com/articles/what-lies-ahead-for-ligand-lgnd-this-earnings-season-revised-2018-05-03", "https://www.nasdaq.com/articles/immune-design-imdz-posts-narrower-than-expected-loss-in-q1-2018-05-03", "https://www.nasdaq.com/articles/what-lies-ahead-for-ligand-lgnd-this-earnings-season-2018-05-02", "https://www.nasdaq.com/articles/amag-pharma-amag-q1-loss-wider-than-expected-lifts-view-2018-05-04", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-q1-earnings-estimates-sales-miss-2018-05-02", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q1-earnings-sales-retains-18-view-2018-05-02", "https://www.nasdaq.com/articles/merck-mrk-beats-on-q1-earnings-lags-sales-raises-outlook-2018-05-01", "https://www.nasdaq.com/articles/allergan-agn-q1-earnings-beat-estimates-sales-up-y-y-2018-04-30", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-incorporated-lgnd-sees-hammer-chart-pattern%3A-time-to-buy-2018-04-30", "https://www.nasdaq.com/articles/medicines-companys-mdco-q1-loss-widens-revenues-tank-y-y-2018-04-27", "https://www.nasdaq.com/articles/alkermes-alks-reports-wider-than-expected-loss-in-q1-2018-04-27", "https://www.nasdaq.com/articles/ironwood-irwd-incurs-loss-in-q1-announces-restructuring-2018-05-02", "https://www.nasdaq.com/articles/sanofis-sny-earnings-beat-estimates-in-q1-sales-miss-mark-2018-04-27", "https://www.nasdaq.com/articles/vertex-vrtx-q1-earnings-beat-on-strong-cf-products-sales-2018-04-27", "https://www.nasdaq.com/articles/roche-rhhby-q1-earnings%3A-ocrevus-perjeta-drive-sales-beat-2018-04-27", "https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-2018-view-up-stock-gains-2018-04-26", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q1-guidance-up-2018-04-26", "https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings-lower-than-expected-sales-beat-2018-04-26", "https://www.nasdaq.com/articles/catalyst-enrolls-first-patient-in-phase-iii-firdapse-study-2018-04-20", "https://www.nasdaq.com/articles/shire-shpg-q1-earnings-beat-rare-disease-franchise-strong-2018-04-27", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-priority-review-for-lung-cancer-2018-04-19", "https://www.nasdaq.com/articles/agios-leukemia-drug-bodes-well-for-growth-strong-pipeline-2018-04-18", "https://www.nasdaq.com/articles/bayer-to-divest-3.6-stake-to-singapore-company-temasek-2018-04-18", "https://www.nasdaq.com/articles/mercks-keytruda-betters-survival-in-lung-cancer-combo-study-2018-04-17", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-data-for-rnai-candidate-2018-04-17", "https://www.nasdaq.com/articles/alkermes-rallies-as-fda-accepts-nda-for-depression-drug-2018-04-17", "https://www.nasdaq.com/articles/intercept-reports-phase-iii-sub-study-liver-biopsy-data-2018-04-16", "https://www.nasdaq.com/articles/calitheras-kidney-cancer-candidate-gets-fast-track-status-2018-04-19", "https://www.nasdaq.com/articles/verastem-vstm-in-focus%3A-stock-moves-8-higher-2018-04-13", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-bellicums-blcm-t-cell-therapy-2018-04-12", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-ligand-arcelormittal-58.com-ameresco-and-mammoth", "https://www.nasdaq.com/articles/karyopharms-myeloma-candidate-gets-fast-track-designation-2018-04-11", "https://www.nasdaq.com/articles/fda-prolongs-review-date-for-abbvie-endometriosis-candidate-2018-04-11", "https://www.nasdaq.com/articles/first-week-november-16th-options-trading-ligand-pharmaceuticals-lgnd-2018-04-11", "https://www.nasdaq.com/articles/5-best-profitable-stocks-offering-amazing-returns-2018-04-11", "https://www.nasdaq.com/articles/rigel-pharmaceuticals-rigl-stock-gains-16%3A-heres-why-2018-04-13", "https://www.nasdaq.com/articles/fda-restricts-sale-of-bayers-essure-birth-control-device-2018-04-10", "https://www.nasdaq.com/articles/ionis-ions-clinches-licensing-agreement-with-astrazeneca-2018-04-10", "https://www.nasdaq.com/articles/novartis-inks-%248.7-billion-gene-therapy-deal-to-buy-avexis-2018-04-09", "https://www.nasdaq.com/articles/clovis-oncology-clvs-surges%3A-stock-moves-5.9-higher-2018-04-09", "https://www.nasdaq.com/articles/fda-okays-label-expansion-of-paciras-exparels-stock-up-2018-04-09", "https://www.nasdaq.com/articles/sonoma-up-on-fda-approval-of-antimicrobial-post-therapy-gel-2018-04-06", "https://www.nasdaq.com/articles/zackscom-highlights-michael-kors-holdings-ligand-pharmaceuticals-tivity-health-nv5-global", "https://www.nasdaq.com/articles/epizyme-epzm-publishes-tazemetostat-phase-i-data-stock-up-2018-04-11", "https://www.nasdaq.com/articles/novo-nordisk-obtains-licence-for-sickle-cell-disease-program-2018-04-06", "https://www.nasdaq.com/articles/conatus-emricasan-fails-in-phase-ii-study-shares-sink-2018-04-05", "https://www.nasdaq.com/articles/explore-driehaus-strategy-with-these-5-momentum-stocks-2018-04-05", "https://www.nasdaq.com/articles/lgnd-crosses-above-average-analyst-target-2018-04-05", "https://www.nasdaq.com/articles/catalyst-cprx-up-on-new-drug-application-for-firdapse-2018-04-05", "https://www.nasdaq.com/articles/bio-path-leukemia-combo-study-shows-positive-early-data-2018-04-04", "https://www.nasdaq.com/articles/ema-accepts-regeneron-sanofis-application-for-dupixent-2018-04-03", "https://www.nasdaq.com/articles/emergent-ebs-gains-86.1-in-a-years-time%3A-heres-why-2018-04-06", "https://www.nasdaq.com/articles/sanofis-sny-skin-cancer-candidate-filing-accepted-in-eu-2018-04-03", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-depression-drug-review-2018-04-03", "https://www.nasdaq.com/articles/edge-therapeutics-loses-edge-on-failure-of-late-stage-study-2018-04-02", "https://www.nasdaq.com/articles/amgens-blincyto-gets-fda-nod-for-minimum-residual-disease-2018-04-02", "https://www.nasdaq.com/articles/4-top-ranked-drug-biotech-stocks-to-buy-as-q1-nears-end-2018-03-27", "https://www.nasdaq.com/articles/regeneron-collaborates-with-alnylam-to-develop-nash-treatment-2018-03-22", "https://www.nasdaq.com/articles/valeant-vrx-stock-declines-21-ytd%3A-what-lies-ahead-2018-03-22", "https://www.nasdaq.com/articles/amgens-amgn-xgeva-gets-eu-approval-for-expanded-label-2018-04-03", "https://www.nasdaq.com/articles/novo-nordisk-poised-on-strong-pipeline-amid-competition-2018-03-21", "https://www.nasdaq.com/articles/ignore-trumps-pricing-rhetoric-these-5-biotech-picks-2018-03-21", "https://www.nasdaq.com/articles/herons-pain-candidate-meets-endpoint-in-pivotal-studies-2018-03-20", "https://www.nasdaq.com/articles/arenas-arna-etrasimod-meets-phase-ii-colitis-study-goal-2018-03-20", "https://www.nasdaq.com/articles/regeneron-eylea-hits-24-week-primary-endpoint-in-study-2018-03-20", "https://www.nasdaq.com/articles/geron-gern-q4-loss-flat-y-y-revenues-surge-shares-up-2018-03-19", "https://www.nasdaq.com/articles/agenus-agen-q4-loss-wider-than-expected-revenues-miss-2018-03-16", "https://www.nasdaq.com/articles/glaxosmithkline-initiates-phase-iii-combo-study-on-benlysta-2018-03-21", "https://www.nasdaq.com/articles/catalyst-cprx-posts-in-line-q4-loss-pipeline-in-progress-2018-03-15", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q4-earnings-beat-sales-down-y-y-2018-03-15", "https://www.nasdaq.com/articles/solid-biosciences-sldb-hit-by-clinical-hold-on-lead-drug-2018-03-15", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q4-2018-03-14", "https://www.nasdaq.com/articles/abbvies-uterine-fibroids-candidate-succeeds-in-phase-iii-2018-03-14", "https://www.nasdaq.com/articles/sarepta-to-seek-rapid-approval-for-second-dmd-drug-stock-up-2018-03-13", "https://www.nasdaq.com/articles/biogen-to-buy-mid-stage-neuropsychiatry-asset-from-pfizer-2018-03-13", "https://www.nasdaq.com/articles/alexion-alxn-gains-on-positive-date-from-lead-candidate-2018-03-16", "https://www.nasdaq.com/articles/aradigm-files-maa-for-bronchiectasis-candidate-in-the-eu-2018-03-12", "https://www.nasdaq.com/articles/regeneron-and-sanofi-announce-positive-data-on-praluent-2018-03-12", "https://www.nasdaq.com/articles/pfizer-gets-fda-panel-backing-for-new-indication-for-xeljanz-2018-03-09", "https://www.nasdaq.com/articles/celldex-cldx-q4-loss-narrows-revenues-beat-shares-up-2018-03-08", "https://www.nasdaq.com/articles/conatus-cnat-loss-narrower-than-expected-in-q4-sales-miss-2018-03-08", "https://www.nasdaq.com/articles/corcept-plans-korlym-label-expansion-pipeline-in-progress-2018-03-08", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-fda-nod-for-every-four-week-dosing-2018-03-08", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2018-03-13", "https://www.nasdaq.com/articles/bayer-basf-in-talks-for-vegetable-seeds-business-sell-off-2018-03-08", "https://www.nasdaq.com/articles/thursdays-etf-movers-pjp-xme-2018-03-08", "https://www.nasdaq.com/articles/spectrum-sppi-q4-loss-widens-y-y-sales-miss-stock-falls-2018-03-07", "https://www.nasdaq.com/articles/dermiras-acne-candidate-fails-in-pivotal-trials-shares-sink-2018-03-06", "https://www.nasdaq.com/articles/validea-motley-fool-strategy-daily-upgrade-report-362018-2018-03-06", "https://www.nasdaq.com/articles/aduro-adro-q4-loss-narrower-than-expected-revenues-miss-2018-03-05", "https://www.nasdaq.com/articles/valeant-vrx-down-on-q4-earnings-miss-issues-drab-18-view-2018-03-05", "https://www.nasdaq.com/articles/lilly-boehringer-to-expand-jardiance-heart-failure-program-2018-03-08", "https://www.nasdaq.com/articles/intrexon-xon-q4-loss-narrower-than-expected-revenues-beat-2018-03-02", "https://www.nasdaq.com/articles/perrigo-prgo-surpassed-earnings-in-q4-revenues-down-y-y-2018-03-02", "https://www.nasdaq.com/articles/puma-pbyi-q4-loss-narrower-than-expected-shares-down-2018-03-02", "https://www.nasdaq.com/articles/impax-ipxl-q4-earnings-revenues-miss-estimates-fall-y-y-2018-03-02", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q4-revenues-in-line-2018-03-02", "https://www.nasdaq.com/articles/sarepta-srpt-narrows-q4-loss-exondys-51-sales-impress-2018-03-02", "https://www.nasdaq.com/articles/9-stocks-buy-instead-bitcoin-2018-03-01", "https://www.nasdaq.com/articles/fda-accepts-regeneron-sanofis-dupixent-sbla-for-asthma-2018-03-05", "https://www.nasdaq.com/articles/amag-pharma-amag-beats-on-q4-earnings-misses-on-revenues-2018-02-28", "https://www.nasdaq.com/articles/ligand-lgnd-q4-earnings-revenues-top-2018-view-solid-2018-02-22", "https://www.nasdaq.com/articles/whats-in-store-for-ligand-lgnd-this-earnings-season-2018-02-19", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-2018-2018-01-29", "https://www.nasdaq.com/articles/omeros-shows-rising-price-performance-jump-81-rs-rating-2018-01-26", "https://www.nasdaq.com/articles/regenxbio-clears-technical-benchmark-hitting-80-plus-rs-rating-2018-01-26", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-scores-relative-strength-rating-upgrade-hits-key-threshold-2018-01", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings-miss-sales-up-y-y-2018-02-28", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-supernus-pharmaceuticals-earns-81-rs-rating-2018", "https://www.nasdaq.com/articles/regenxbio-earns-relative-strength-rating-upgrade-hits-key-benchmark-2018-01-24", "https://www.nasdaq.com/articles/gw-pharmaceuticals-meets-80-plus-relative-strength-rating-benchmark-2018-01-24", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-shows-rising-price-performance-jump-85-rs-rating-2018-01-24", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-sees-ibd-rs-rating-improve-74-2018-01-24", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-la-jolla-pharmaceutical-2018-01-24", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-omeros-2018-01-24", "https://www.nasdaq.com/articles/stocks-watch-tg-therapeutics-sees-relative-strength-rating-jump-92-2018-01-26", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-array-biopharma-earns-96-rs-rating-2018-01-23", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-exelixis-2018-01-23", "https://www.nasdaq.com/articles/tg-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2018-01-23", "https://www.nasdaq.com/articles/agios-pharmaceuticals-joins-rank-stocks-rs-ratings-over-90-2018-01-23", "https://www.nasdaq.com/articles/stocks-watch-acorda-therapeutics-sees-rs-rating-jump-84-2018-01-22", "https://www.nasdaq.com/articles/ibd-rating-upgrades-innoviva-shows-improved-technical-strength-2018-01-22", "https://www.nasdaq.com/articles/10-stocks-buy-instead-bitcoin-2018-01-19", "https://www.nasdaq.com/articles/stocks-showing-improved-relative-strength-regenxbio-2018-01-23", "https://www.nasdaq.com/articles/5-big-biotech-stocks-buy-2018-2018-01-17", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-voyager-therapeutics-earns-91-rs-rating-2018-01-16", "https://www.nasdaq.com/articles/stock-gains-vanish-small-caps-reverse-lower-2018-01-16", "https://www.nasdaq.com/articles/ligand-lgnd-inks-deal-with-glenmark-for-omniab-platform-2018-01-12", "https://www.nasdaq.com/articles/atara-biotherapeutics-joins-elite-club-stocks-rs-ratings-over-90-2018-01-12", "https://www.nasdaq.com/articles/biogen-trying-close-key-technical-measure-2018-01-11", "https://www.nasdaq.com/articles/omeros-scores-relative-strength-rating-upgrade-hits-key-threshold-2018-01-11", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-biogen-2018-01-18", "https://www.nasdaq.com/articles/stocks-watch-halozyme-therapeutics-sees-rs-rating-rise-92-2018-01-11", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-meets-80-plus-relative-strength-rating-benchmark-2018-01-11", "https://www.nasdaq.com/articles/heron-therapeutics-joins-elite-club-stocks-rs-ratings-over-90-2018-01-11", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-regenxbio-2018-01-11", "https://www.nasdaq.com/articles/supernus-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2018-01", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-array-biopharma-earns-91-rs-rating-2018-01-10", "https://www.nasdaq.com/articles/portola-pharmaceuticals-reaches-80-plus-relative-strength-rating-benchmark-2018-01-10", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-agios-pharmaceuticals-earns-81-rs-rating-2018", "https://www.nasdaq.com/articles/ptc-therapeutics-clears-key-benchmark-hitting-80-plus-rs-rating-2018-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-gwph-submits-epidiolex-eu-sangamo-inks-deal-pfizer-2018-01-04", "https://www.nasdaq.com/articles/18-reasons-i-biotech-stocks-2018-2018-01-04", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-biogen-2018-01-03", "https://www.nasdaq.com/articles/ptc-therapeutics-shows-market-leadership-jump-84-rs-rating-2018-01-03", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-hits-80-plus-relative-strength-rating-benchmark-2018-01-03", "https://www.nasdaq.com/articles/flexion-therapeutics-getting-closer-key-technical-measure-2017-12-29", "https://www.nasdaq.com/articles/avexis-joins-rank-stocks-rs-ratings-over-90-2018-01-09", "https://www.nasdaq.com/articles/health-care-sector-update-12262017-lgndigcinsyabbv-2017-12-26", "https://www.nasdaq.com/articles/gw-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-benchmark-2017-12-15", "https://www.nasdaq.com/articles/clovis-oncology-shows-rising-relative-strength-still-shy-key-threshold-2017-12-15", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-ptc-therapeutics-2017-12-15", "https://www.nasdaq.com/articles/3-growth-stocks-id-buy-right-now-2017-12-10", "https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-now-2017-12-03", "https://www.nasdaq.com/articles/3-stocks-could-put-alibabas-returns-shame-2017-11-30", "https://www.nasdaq.com/articles/supernus-pharmaceuticals-shows-rising-price-performance-jump-81-rs-rating-2017-12-29", "https://www.nasdaq.com/articles/medicines-company-to-sell-infectious-disease-unit-to-melinta-2017-11-30", "https://www.nasdaq.com/articles/merck-announces-%2410-billion-buyback-hikes-dividend-by-2.1-2017-11-29", "https://www.nasdaq.com/articles/glaxo-submits-nda-for-anti-relapse-malaria-medicine-to-fda-2017-11-29", "https://www.nasdaq.com/articles/astrazenecas-tagrisso-label-expansion-filing-accepted-by-ema-2017-11-29", "https://www.nasdaq.com/articles/3-growth-stocks-long-term-2017-11-29", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-revised-2017-11-29", "https://www.nasdaq.com/articles/astrazeneca-files-for-label-expansion-of-tagrisso-in-japan-2017-11-28", "https://www.nasdaq.com/articles/is-gw-pharma-gwph-likely-to-beat-earnings-estimates-in-q4-2017-11-30", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-2017-11-28", "https://www.nasdaq.com/articles/spectrum-doubles-in-3-months%3A-whats-driving-the-rally-2017-11-27", "https://www.nasdaq.com/articles/glaxo-gsk-files-for-u.s.-label-expansion-of-copd-inhaler-2017-11-23", "https://www.nasdaq.com/articles/puma-inks-license-deal-to-commercialize-cancer-drug-nerlynx-2017-11-23", "https://www.nasdaq.com/articles/lilly-inks-deal-to-include-dexcom-products-in-diabetes-system-2017-11-22", "https://www.nasdaq.com/articles/catalyst-initiates-phase-ii-study-for-pipeline-drug-firdapse-2017-11-22", "https://www.nasdaq.com/articles/valeant-closes-senior-note-offering-reprices-term-loan-2017-11-22", "https://www.nasdaq.com/articles/catalyst-cprx-reports-positive-phase-iii-data-on-firdapse-2017-11-28", "https://www.nasdaq.com/articles/can-valeant-vrx-turn-around-on-rebuilding-initiatives-2017-11-21", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-intra-cellular-therapies-2017-11-21", "https://www.nasdaq.com/articles/roche-reports-positive-data-from-tecentriq-combination-study-2017-11-20", "https://www.nasdaq.com/articles/mallinckrodt-mnk-down-55-year-to-date%3A-what-lies-ahead-2017-11-20", "https://www.nasdaq.com/articles/agios-posts-new-data-on-glioma-candidate-from-dose-expansion-2017-11-20", "https://www.nasdaq.com/articles/supernus-pharmaceuticals-shows-rising-price-performance-jump-83-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-zynerba-pharmaceuticals-2017-11-20", "https://www.nasdaq.com/articles/alnylams-rnai-candidate-gains-breakthrough-therapy-status-2017-11-21", "https://www.nasdaq.com/articles/ibd-rating-upgrades-biogen-shows-improved-price-strength-2017-11-20", "https://www.nasdaq.com/articles/acceleron-pharma-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/alnylam-starts-rolling-nda-submission-for-rnai-candidate-2017-11-17", "https://www.nasdaq.com/articles/ultragenyxs-rhgus-gets-fda-nod-for-rare-genetic-disease-2017-11-17", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-regenxbio-2017-11-16", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-shows-market-leadership-jump-81-rs-rating-2017-11-16", "https://www.nasdaq.com/articles/stocks-watch-flexion-therapeutics-sees-rs-rating-jump-83-2017-11-16", "https://www.nasdaq.com/articles/exelixis-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/ibd-rating-upgrades-biogen-shows-improved-price-strength-2017-11-20", "https://www.nasdaq.com/articles/acceleron-pharma-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-11-20", "https://www.nasdaq.com/articles/alnylam-starts-rolling-nda-submission-for-rnai-candidate-2017-11-17", "https://www.nasdaq.com/articles/ultragenyxs-rhgus-gets-fda-nod-for-rare-genetic-disease-2017-11-17", "https://www.nasdaq.com/articles/merck-mrk-gets-chmp-nod-for-infection-candidate-prevymis-2017-11-14", "https://www.nasdaq.com/articles/theravance-tbph-submits-nda-for-copd-candidate-revefenacin-2017-11-14", "https://www.nasdaq.com/articles/valeant-vrx-announces-pricing-of-senior-secured-notes-2017-11-15", "https://www.nasdaq.com/articles/paciras-exparel-snda-to-be-reviewed-by-fda-advisory-committee-2017-11-15", "https://www.nasdaq.com/articles/lgnd-crosses-above-average-analyst-target-2017-11-15", "https://www.nasdaq.com/articles/vertex-gets-chmp-recommendation-for-orkambi-label-expansion-2017-11-13", "https://www.nasdaq.com/articles/endo-endp-earnings-revenues-beat-in-q3-generics-weak-2017-11-10", "https://www.nasdaq.com/articles/biodelivery-bdsi-q3-earnings-sales-beat-estimates-2017-11-10", "https://www.nasdaq.com/articles/ligand-lgnd-q3-earnings-revenues-top-2017-view-raised-2017-11-10", "https://www.nasdaq.com/articles/omeros-scores-relative-strength-rating-upgrade-hits-key-benchmark-2017-11-14", "https://www.nasdaq.com/articles/intrexon-xon-q3-loss-narrower-than-expected-revenues-miss-2017-11-10", "https://www.nasdaq.com/articles/stocks-watch-intra-cellular-therapies-sees-rs-rating-rise-88-2017-11-10", "https://www.nasdaq.com/articles/perrigo-prgo-q3-earnings-top-2017-view-raised-shares-up-2017-11-09", "https://www.nasdaq.com/articles/merrimack-mack-q3-loss-narrower-than-expected-stock-up-2017-11-09", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q3-revenues-lag-estimates-2017-11-09", "https://www.nasdaq.com/articles/catalyst-cprx-posts-narrower-than-expected-loss-in-q3-2017-11-09", "https://www.nasdaq.com/articles/puma-biotechnology-flops-despite-topping-sales-loss-expectations-2017-11-09", "https://www.nasdaq.com/articles/puma-pbyi-falls-despite-narrower-than-expected-q3-loss-2017-11-10", "https://www.nasdaq.com/articles/intrexon-xon-q3-loss-narrower-than-expected-revenues-miss-2017-11-10", "https://www.nasdaq.com/articles/stocks-watch-intra-cellular-therapies-sees-rs-rating-rise-88-2017-11-10", "https://www.nasdaq.com/articles/perrigo-prgo-q3-earnings-top-2017-view-raised-shares-up-2017-11-09", "https://www.nasdaq.com/articles/merrimack-mack-q3-loss-narrower-than-expected-stock-up-2017-11-09", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q3-revenues-lag-estimates-2017-11-09", "https://www.nasdaq.com/articles/catalyst-cprx-posts-narrower-than-expected-loss-in-q3-2017-11-09", "https://www.nasdaq.com/articles/puma-biotechnology-flops-despite-topping-sales-loss-expectations-2017-11-09", "https://www.nasdaq.com/articles/valeant-vrx-earnings-and-revenues-beat-in-q3-stock-up-2017-11-09", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-achaogen-2017-11-09", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-9-2017-dis-nvda-jwn-mscc-nwsa-al-pbyi-icui-avxs-lgnd", "https://www.nasdaq.com/articles/mallinckrodt-mnk-earnings-sales-decline-y-y-in-q3-2017-11-08", "https://www.nasdaq.com/articles/agenus-agen-reports-in-line-loss-in-q3-revenues-lag-2017-11-08", "https://www.nasdaq.com/articles/biogen-shows-rising-relative-strength-still-shy-key-threshold-2017-11-06", "https://www.nasdaq.com/articles/flexion-therapeutics-getting-closer-key-technical-measure-2017-11-06", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q3-earnings-beat-revenues-rise-y-y-2017-11-03", "https://www.nasdaq.com/articles/prothena-prta-earnings-beat-in-q3-pipeline-in-focus-2017-11-08", "https://www.nasdaq.com/articles/strange-bullish-lgnd-analysts-actually-see-13-downside-2017-11-03", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-adds-10.3-in-session-2017-11-03", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-scores-relative-strength-rating-upgrade-hits-key-threshold-2017-11", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-neurocrine-biosciences-earns-96-rs-rating-2017-11-03", "https://www.nasdaq.com/articles/exelixis-scores-relative-strength-rating-upgrade-2017-11-03", "https://www.nasdaq.com/articles/corcept-cort-q3-earnings-miss-estimates-guidance-raised-2017-11-03", "https://www.nasdaq.com/articles/agios-agio-q3-loss-narrower-than-expected-revenues-up-y-y-2017-11-02", "https://www.nasdaq.com/articles/amag-pharmas-amag-q3-earnings-beat-lowers-17-outlook-2017-11-03", "https://www.nasdaq.com/articles/strange-bullish-lgnd-analysts-actually-see-13-downside-2017-11-03", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-soars%3A-stock-adds-10.3-in-session-2017-11-03", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-scores-relative-strength-rating-upgrade-hits-key-threshold-2017-11", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-neurocrine-biosciences-earns-96-rs-rating-2017-11-03", "https://www.nasdaq.com/articles/acorda-acor-q3-earnings-lag-estimates-revenues-up-y-y-2017-11-01", "https://www.nasdaq.com/articles/novartis-buys-french-radiopharmaceutical-company-2017-10-31", "https://www.nasdaq.com/articles/immune-design-imdz-posts-narrower-than-expected-loss-in-q3-2017-11-02", "https://www.nasdaq.com/articles/sarepta-therapeutics-clears-key-benchmark-hitting-90-plus-rs-rating-2017-10-31", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-adamas-pharmaceuticals-2017-10-31", "https://www.nasdaq.com/articles/intra-cellular-therapies-earns-relative-strength-rating-upgrade-2017-10-31", "https://www.nasdaq.com/articles/ibd-rating-upgrades-seattle-genetics-flashes-improved-price-strength-2017-10-30", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-82-2017-10-30", "https://www.nasdaq.com/articles/la-jolla-pharmaceutical-earns-relative-strength-rating-upgrade-2017-10-30", "https://www.nasdaq.com/articles/alkermes-alks-beats-q3-earnings-estimates-cuts-sales-view-2017-10-27", "https://www.nasdaq.com/articles/biogen-sees-relative-strength-rating-climb-75-2017-10-31", "https://www.nasdaq.com/articles/sarepta-therapeutics-clears-key-benchmark-hitting-90-plus-rs-rating-2017-10-31", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-10-26", "https://www.nasdaq.com/articles/alexion-alxn-tops-q3-earnings-lags-sales-2017-view-up-2017-10-26", "https://www.nasdaq.com/articles/3-small-profitable-biotechs-fantastic-growth-2017-10-24", "https://www.nasdaq.com/articles/aimmune-therapeutics-scores-relative-strength-rating-upgrade-2017-10-24", "https://www.nasdaq.com/articles/abbvie-inks-immuno-oncology-deal-with-harpoon-therapeutics-2017-10-20", "https://www.nasdaq.com/articles/innoviva-clears-key-benchmark-hitting-80-plus-rs-rating-2017-10-20", "https://www.nasdaq.com/articles/bayer-bayry-q3-earnings-beat-estimates-sales-down-y-y-2017-10-27", "https://www.nasdaq.com/articles/novartis-reports-positive-results-on-thrombocytopenia-drug-2017-10-19", "https://www.nasdaq.com/articles/impax-laboratories-and-amneal-pharmaceuticals-agree-to-merge-2017-10-18", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-novo-vertex-pharmaceuticals-celgene-and-ligand", "https://www.nasdaq.com/articles/inovio-initiates-bladder-cancer-study-with-roches-tecentriq-2017-10-17", "https://www.nasdaq.com/articles/innovative-pipelines-regulatory-catalysts-drive-pharma-stocks-2017-10-17", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-ptc-therapeutics-earns-92-rs-rating-2017-10-17", "https://www.nasdaq.com/articles/exelixis-earns-relative-strength-rating-upgrade-2017-10-17", "https://www.nasdaq.com/articles/gilead-sciences-shows-rising-relative-price-performance-still-shy-key-threshold-2017-10-20", "https://www.nasdaq.com/articles/acelrxs-opioid-painkiller-dsuvia-gets-crl-shares-plunge-2017-10-13", "https://www.nasdaq.com/articles/intra-cellular-therapies-shows-rising-price-performance-jump-83-rs-rating-2017-10-12", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-ionis-pharmaceuticals-2017-10-12", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-scores-relative-strength-rating-upgrade-2017-10-12", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-aerie-pharmaceuticals-earns-82-rs-rating-2017-10", "https://www.nasdaq.com/articles/forget-teva-teva-buy-these-5-drug-stocks-instead-2017-10-09", "https://www.nasdaq.com/articles/flexion-therapeutics-clears-technical-benchmark-hitting-90-plus-rs-rating-2017-10-09", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-2017", "https://www.nasdaq.com/articles/flexion-therapeutics-hits-80-plus-relative-strength-rating-benchmark-2017-10-06", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-innoviva-2017-10-06", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-92-2017-10-06", "https://www.nasdaq.com/articles/ligand-lgnd-signs-deal-to-acquire-crystal-bioscience-2017-10-05", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-soars%3A-stock-adds-9.2-in-session-2017-10-05", "https://www.nasdaq.com/articles/palatin-technologies-ptn-in-focus%3A-stock-moves-13.2-higher-2017-10-05", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-amgen-2017-10-05", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-intra-cellular-therapies-earns-83-rs-rating", "https://www.nasdaq.com/articles/global-blood-therapeutic-earns-relative-strength-rating-upgrade-2017-10-05", "https://www.nasdaq.com/articles/stocks-rising-relative-strength-intra-cellular-therapies-2017-10-05", "https://www.nasdaq.com/articles/lgnd-crosses-above-average-analyst-target-2017-10-04", "https://www.nasdaq.com/articles/catabasis-pharmaceuticals-catb-surges%3A-stock-moves-7.2-higher-2017-10-04", "https://www.nasdaq.com/articles/mannkind-mnkd-in-focus%3A-stock-moves-7.8-higher-2017-10-03", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-innoviva-2017-10-03", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-2017-10-05", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-flexion-therapeutics-earns-85-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/acorda-therapeutics-shows-market-leadership-jump-91-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-acceleron-pharma-2017-09-29", "https://www.nasdaq.com/articles/flexion-therapeutics-sees-relative-strength-rating-improve-75-2017-09-29", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/ligand-pharma-chipotle-mexican-grill-arcelormittal-ichor-holdings-and-micron-technology", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-73-2017-10-03", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-flexion-therapeutics-earns-85-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/acorda-therapeutics-shows-market-leadership-jump-91-rs-rating-2017-10-03", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-acceleron-pharma-2017-09-29", "https://www.nasdaq.com/articles/flexion-therapeutics-sees-relative-strength-rating-improve-75-2017-09-29", "https://www.nasdaq.com/articles/ionis-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/ligand-pharma-chipotle-mexican-grill-arcelormittal-ichor-holdings-and-micron-technology", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-73-2017-10-03", "https://www.nasdaq.com/articles/ascendis-pharma-asnd-looks-good%3A-stock-adds-5.5-in-session-2017-09-26", "https://www.nasdaq.com/articles/aimmune-therapeutics-aimt-in-focus%3A-stock-moves-6.3-higher-2017-09-26", "https://www.nasdaq.com/articles/3-stocks-nike-return-potential-2017-09-23", "https://www.nasdaq.com/articles/alcoa-cheesecake-factory-luminex-ligand-pharmaceuticals-and-centene-highlighted-as-zacks", "https://www.nasdaq.com/articles/3-healthcare-stocks-buy-renewed-obamacare-repeal-talks-2017-09-19", "https://www.nasdaq.com/articles/glaxos-shingles-candidate-gets-positive-fda-committee-vote-2017-09-14", "https://www.nasdaq.com/articles/pfizer-lung-cancer-drugs-overall-survival-data-unfavorable-2017-09-12", "https://www.nasdaq.com/articles/bull-day-ligand-pharma-lgnd-2017-09-27", "https://www.nasdaq.com/articles/lilly-to-cut-3500-jobs-to-invest-in-new-drugs-and-growth-2017-09-08", "https://www.nasdaq.com/articles/alnylam-shares-plunge-on-patient-death-dosing-suspended-2017-09-08", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-combo-gets-priority-review-in-u.s.-2017-08-25", "https://www.nasdaq.com/articles/strength-seen-in-myovant-sciences-myov%3A-stock-soars-16.1-2017-08-18", "https://www.nasdaq.com/articles/can-ligands-captisol-deals-boost-growth-in-the-long-run-2017-08-15", "https://www.nasdaq.com/articles/rk-capital-management-llc-buys-electronics-imaging-inc-douglas-dynamics-inc-kbr-inc-2017", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-05", "https://www.nasdaq.com/articles/can-ligand-lgnd-pull-a-surprise-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/invest-royalty-these-3-stocks-2017-07-18", "https://www.nasdaq.com/articles/ligand-signs-agreement-with-amgen-grants-rights-to-captisol-2017-07-18", "https://www.nasdaq.com/articles/3-hot-stocks-buy-july-2017-07-10", "https://www.nasdaq.com/articles/ligand-gets-milestone-payment-on-partner-drug-fda-approval-2017-06-21", "https://www.nasdaq.com/articles/why-is-ligand-pharmaceuticals-lgnd-up-5.1-since-the-last-earnings-report-2017-06-13", "https://www.nasdaq.com/articles/key-fda-events-watch-out-jun-2017-2017-06-05", "https://www.nasdaq.com/articles/ligand-lgnd-q2-earnings-revenues-top-2017-view-raised-2017-08-08", "https://www.nasdaq.com/articles/can-ligand-lgnd-pull-a-surprise-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/invest-royalty-these-3-stocks-2017-07-18", "https://www.nasdaq.com/articles/ligand-signs-agreement-with-amgen-grants-rights-to-captisol-2017-07-18", "https://www.nasdaq.com/articles/can-ligand-lgnd-spring-a-surprise-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-iac-lgnd-watt-2017-05-02", "https://www.nasdaq.com/articles/lgnd-makes-bullish-cross-above-critical-moving-average-2017-04-25", "https://www.nasdaq.com/articles/3-stocks-apple-return-potential-2017-04-11", "https://www.nasdaq.com/articles/ligand-lgnd-signs-licensing-deal-with-xcella-biosciences-2017-05-31", "https://www.nasdaq.com/articles/these-3-stocks-look-expensive-are-actually-cheap-2017-05-11", "https://www.nasdaq.com/articles/heres-why-organovo-holdings-stock-fell-52-april-2017-05-11", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-q1-earnings-miss-estimates-2017-05-10", "https://www.nasdaq.com/articles/can-ligand-lgnd-spring-a-surprise-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-iac-lgnd-watt-2017-05-02", "https://www.nasdaq.com/articles/lgnd-makes-bullish-cross-above-critical-moving-average-2017-04-25", "https://www.nasdaq.com/articles/3-stocks-apple-return-potential-2017-04-11", "https://www.nasdaq.com/articles/ligand-lgnd-signs-licensing-deal-with-xcella-biosciences-2017-05-31", "https://www.nasdaq.com/articles/these-3-stocks-look-expensive-are-actually-cheap-2017-05-11", "https://www.nasdaq.com/articles/heres-why-organovo-holdings-stock-fell-52-april-2017-05-11", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-q1-earnings-miss-estimates-2017-05-10", "https://www.nasdaq.com/articles/can-ligand-lgnd-spring-a-surprise-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-iac-lgnd-watt-2017-05-02", "https://www.nasdaq.com/articles/lgnd-makes-bullish-cross-above-critical-moving-average-2017-04-25", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-rgr-rad-lgnd-2017-01-18", "https://www.nasdaq.com/articles/4-biotech-stocks-buy-january-2016-12-26", "https://www.nasdaq.com/articles/ligand-lgnd-signs-licensing-deals-with-ono-and-novartis-2016-12-23", "https://www.nasdaq.com/articles/health-care-sector-update-12222016-lgnd-2016-12-22", "https://www.nasdaq.com/articles/why-ligand-pharmaceuticals-lgnd-stock-might-be-a-great-pick-2016-12-16", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-lgnd-ter-ostk-2016-12-14", "https://www.nasdaq.com/articles/3-top-growth-stocks-buy-2017-2016-12-14", "https://www.nasdaq.com/articles/3-biotech-stocks-id-buy-right-now-2017-01-29", "https://www.nasdaq.com/articles/ligands-partner-retrophin-provides-new-data-on-sparsentan-2016-11-22", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-own-if-donald-trump-becomes-president-2016-11-06", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-now-oversold-lgnd-2016-11-03", "https://www.nasdaq.com/articles/ligand-lgnd-q3-earnings%3A-is-the-stock-likely-to-disappoint-2016-10-28", "https://www.nasdaq.com/articles/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-2016-10-25", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-october-5th-2016-10-05", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-october-2016-10-02", "https://www.nasdaq.com/articles/best-healthcare-stocks-2017-2016-12-10", "https://www.nasdaq.com/articles/amgens-multiple-myeloma-drug-kyprolis-fails-in-phase-iii-2016-09-28", "https://www.nasdaq.com/articles/kite-pharma-reports-favorable-data-from-lymphoma-study-2016-09-27", "https://www.nasdaq.com/articles/analysts-forecast-14-upside-iyh-2016-09-27", "https://www.nasdaq.com/articles/gw-pharma-attains-52-week-high-on-positive-epidiolex-data-2016-09-27", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-enters-oversold-territory-lgnd-2016-09-27", "https://www.nasdaq.com/articles/heres-why-ligand-pharmaceuticals-inc-plunging-today-2016-09-27", "https://www.nasdaq.com/articles/endo-appoints-new-ceo-keeps-q3-16-view-stock-jumps-2016-09-26", "https://www.nasdaq.com/articles/it-too-late-get-millionaire-maker-stock-2016-09-30", "https://www.nasdaq.com/articles/regeneron-sanofi-skin-disease-drug-under-priority-review-2016-09-26", "https://www.nasdaq.com/articles/ligand-inks-cns-license-agreement-with-seelos-therapeutics-2016-09-23", "https://www.nasdaq.com/articles/teva-reports-positive-phase-iii-tardive-dyskinesia-data-2016-09-23", "https://www.nasdaq.com/articles/health-care-sector-update-09222016-lgndavxlblue-2016-09-22", "https://www.nasdaq.com/articles/ligand-lgnd-inks-deal-with-teneobio-for-omniab-technology-2016-09-19", "https://www.nasdaq.com/articles/novartis-reports-positive-phase-ii-data-on-migraine-drug-2016-09-16", "https://www.nasdaq.com/articles/epizyme-receives-milestone-from-glaxo-for-lymphoma-drug-2016-09-16", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-sale-2016-09-26", "https://www.nasdaq.com/articles/roche-ocrevus-positive-in-phase-iii-multiple-sclerosis-trials-2016-09-15", "https://www.nasdaq.com/articles/shires-immunodeficiency-treatment-cuvitru-gets-fda-approval-2016-09-15", "https://www.nasdaq.com/articles/ligand-lgnd-commences-phase-ii-type-ii-diabetes-study-2016-09-14", "https://www.nasdaq.com/articles/5-biotech-stocks-are-broker-favorites-2016-09-13", "https://www.nasdaq.com/articles/4-top-stocks-track-double-their-sales-and-profits-2019-2016-09-13", "https://www.nasdaq.com/articles/ligand-retrophin-rare-disease-drug-positive-in-phase-ii-2016-09-08", "https://www.nasdaq.com/articles/why-shares-retrophin-inc-are-soaring-today-2016-09-07", "https://www.nasdaq.com/articles/commit-purchase-ligand-pharmaceuticals-100-earn-108-annualized-using-options-2016-09-15", "https://www.nasdaq.com/articles/these-3-stocks-are-over-700-last-5-years-2016-08-23", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-is-in-oversold-territory%3A-whats-next-2016-08-19", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-shares-cross-below-200-dma-2016-08-17", "https://www.nasdaq.com/articles/we-did-math-pth-can-go-54-2016-08-17", "https://www.nasdaq.com/articles/4-top-biotech-stocks-can-be-purchased-cheap-summer-2016-08-16", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ligand-pharmaceuticals-ormat-technologies-activision", "https://www.nasdaq.com/articles/5-stocks-to-play-momentum-the-driehaus-way-2016-08-11", "https://www.nasdaq.com/articles/lgnd-makes-bullish-cross-above-critical-moving-average-2016-09-07", "https://www.nasdaq.com/articles/endocyte-ecyt-q2-loss-wider-than-expected-revised-2016-08-09", "https://www.nasdaq.com/articles/licensing-agreements-drive-ligand-pharmaceuticals-inc-13-higher-july-2016-08-08", "https://www.nasdaq.com/articles/ligand-lgnd-q2-earnings-decline-yy-maintains-view-2016-08-05", "https://www.nasdaq.com/articles/ligand-lgnd-beats-q2-earnings-revenues-up-y-y-2016-08-04", "https://www.nasdaq.com/articles/ligand-lgnd-q2-earnings-whats-store-stock-2016-08-02", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-reaches-analyst-target-price-2016-07-21", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-5.5-2016-07-21", "https://www.nasdaq.com/articles/inovio-ino-q2-loss-in-line-with-estimates-revenues-top-2016-08-09", "https://www.nasdaq.com/articles/3-most-unbelievably-undervalued-healthcare-stocks-2016-07-13", "https://www.nasdaq.com/articles/heres-why-sage-therapeutics-inc-surging-today-2016-07-12", "https://www.nasdaq.com/articles/ligand-lgnd-signs-deal-with-gilead-for-omniab-technology-2016-07-11", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-sale-right-now-2016-06-29", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-looking-cheap-2016-06-24", "https://www.nasdaq.com/articles/7-profitable-medical-stocks-ranked-buys-now-2016-06-21", "https://www.nasdaq.com/articles/7-biotech-stocks-that-are-buys-right-now-2016-06-17", "https://www.nasdaq.com/articles/3-biotech-stocks-conservative-investors-2016-07-17", "https://www.nasdaq.com/articles/3-incredibly-cheap-biotech-stocks-2016-06-02", "https://www.nasdaq.com/articles/analysts-see-12-gains-ahead-holdings-pwc-2016-06-01", "https://www.nasdaq.com/articles/3-growth-stocks-buy-june-2016-05-28", "https://www.nasdaq.com/articles/3-highly-rated-ibd-stocks-powering-top-biotech-etfs-revival-2016-05-27", "https://www.nasdaq.com/articles/ligand-lgnd-tops-q1-earnings-revenues-updates-view-2016-05-05", "https://www.nasdaq.com/articles/ligand-lgnd-beats-q1-earnings-and-revenue-estimates-2016-05-04", "https://www.nasdaq.com/articles/biotech-stocks-earnings-preview%3A-regn-lgnd-ecyt-more-2016-05-03", "https://www.nasdaq.com/articles/forget-biogen-biib-buy-these-5-biotech-stocks-instead-2016-06-08", "https://www.nasdaq.com/articles/ligand-pharma-adds-tech-grows-partners-success-2016-04-29", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-continue-to-surge-higher-2016-04-08", "https://www.nasdaq.com/articles/analysts-anticipate-10-gains-ahead-holdings-ezm-2016-03-24", "https://www.nasdaq.com/articles/5-growth-stocks-buy-march-2016-03-19", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-lgnd-2016-02-26", "https://www.nasdaq.com/articles/small-cap-etfs-stride-ahead-investors-turn-optimistic-oil-gdp-2016-02-26", "https://www.nasdaq.com/articles/bristol-myers-inks-immuno-oncology-deal-with-dana-farber-2016-02-17", "https://www.nasdaq.com/articles/ligand-lgnd-q1-earnings-whats-store-stock-2016-05-02", "https://www.nasdaq.com/articles/merck-mrk-gets-crl-for-zetia-vytorin-snda-from-fda-2016-02-16", "https://www.nasdaq.com/articles/clovis-clvs-rociletinib-to-face-fda-advisory-panel-in-april-2016-02-15", "https://www.nasdaq.com/articles/eli-lillys-alimta-gets-negative-ruling-in-uk-patent-lawsuit-2016-02-15", "https://www.nasdaq.com/articles/alnylam-alny-reports-wider-q4-loss-revenues-miss-2016-02-12", "https://www.nasdaq.com/articles/incyte-incy-beats-on-q4-earnings-and-revenue-estimates-2016-02-12", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q4-earnings-raises-2016-outlook-2016-02-11", "https://www.nasdaq.com/articles/alkermes-alks-3831-in-2nd-phase-iii-study-for-schizophrenia-2016-02-11", "https://www.nasdaq.com/articles/gileads-hcv-drug-harvoni-approved-in-two-more-indications-2016-02-17", "https://www.nasdaq.com/articles/actelion-aliof-misses-q4-earnings-revenue-estimates-2016-02-10", "https://www.nasdaq.com/articles/cytori-tanks-on-unfavorable-data-from-osteoarthritis-study-2016-02-09", "https://www.nasdaq.com/articles/epizymes-tazemetostat-gets-orphan-drug-status-in-the-u.s.-2016-02-09", "https://www.nasdaq.com/articles/cempra-reports-positive-data-on-antibiotic-solithromycin-2016-02-09", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd%3A-q4-earnings-preview-2016-02-08", "https://www.nasdaq.com/articles/vertex-vrtx-down-crl-kalydeco-label-expansion-2016-02-08", "https://www.nasdaq.com/articles/bristol-myers-daklinza-sovaldi-label-expanded-by-the-fda-2016-02-08", "https://www.nasdaq.com/articles/insys-insy-initiates-phase-ii-study-for-infantile-spasms-2016-02-10", "https://www.nasdaq.com/articles/actelion-aliof-misses-q4-earnings-revenue-estimates-2016-02-10", "https://www.nasdaq.com/articles/cytori-tanks-on-unfavorable-data-from-osteoarthritis-study-2016-02-09", "https://www.nasdaq.com/articles/epizymes-tazemetostat-gets-orphan-drug-status-in-the-u.s.-2016-02-09", "https://www.nasdaq.com/articles/cempra-reports-positive-data-on-antibiotic-solithromycin-2016-02-09", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd%3A-q4-earnings-preview-2016-02-08", "https://www.nasdaq.com/articles/exelixis-cabozantinib-positive-in-renal-cell-carcinoma-study-2016-02-02", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-iii-study-on-spi-2012-2016-02-01", "https://www.nasdaq.com/articles/immunogen-merck-collaborate-for-ovarian-cancer-study-2016-02-05", "https://www.nasdaq.com/articles/dipexium-progresses-on-phase-iii-diabetic-foot-ulcer-studies-2016-02-05", "https://www.nasdaq.com/articles/lgnd-makes-notable-cross-below-critical-moving-average-2016-02-03", "https://www.nasdaq.com/articles/synthetic-biologics-tanks-on-unfavorable-trimesta-data-2016-02-03", "https://www.nasdaq.com/articles/first-week-march-18th-options-trading-ligand-pharmaceuticals-lgnd-2016-02-02", "https://www.nasdaq.com/articles/avalanche-aavl-set-to-acquire-annapurna-therapeutics-2016-02-02", "https://www.nasdaq.com/articles/exelixis-cabozantinib-positive-in-renal-cell-carcinoma-study-2016-02-02", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-iii-study-on-spi-2012-2016-02-01", "https://www.nasdaq.com/articles/immunogen-merck-collaborate-for-ovarian-cancer-study-2016-02-05", "https://www.nasdaq.com/articles/dipexium-progresses-on-phase-iii-diabetic-foot-ulcer-studies-2016-02-05", "https://www.nasdaq.com/articles/lgnd-makes-notable-cross-below-critical-moving-average-2016-02-03", "https://www.nasdaq.com/articles/mannkind-mnkd-signs-deal-with-receptor-life-sciences-2016-01-22", "https://www.nasdaq.com/articles/alkermes-hit-52-week-low-on-unfavorable-phase-iii-data-2016-01-22", "https://www.nasdaq.com/articles/cymabay-gives-update-on-phase-iii-program-on-arhalofenate-2016-01-21", "https://www.nasdaq.com/articles/orexigen-targets-profitability-2018-focus-contrave-2016-01-12", "https://www.nasdaq.com/articles/surmodics-buys-normedix-for-%2414m-adjusts-2016-outlook-2016-01-12", "https://www.nasdaq.com/articles/impaxs-emverm-approved-for-parasitic-worm-infestations-2016-01-19", "https://www.nasdaq.com/articles/biomarins-dmd-drug-kyndrisa-receives-crl-from-the-fda-2016-01-15", "https://www.nasdaq.com/articles/ligand-emergent-biosolutions-tie-up-for-omniab-technology-2016-01-14", "https://www.nasdaq.com/articles/esperion-espr-initiates-phase-iii-study-for-hyperlipidemia-2016-01-14", "https://www.nasdaq.com/articles/alnylam-provides-update-on-rnai-therapeutics-pipeline-2016-01-13", "https://www.nasdaq.com/articles/acordas-ampyra-ends-2015-strong-note-pipeline-focus-2016-01-12", "https://www.nasdaq.com/articles/orexigen-targets-profitability-2018-focus-contrave-2016-01-12", "https://www.nasdaq.com/articles/surmodics-buys-normedix-for-%2414m-adjusts-2016-outlook-2016-01-12", "https://www.nasdaq.com/articles/impaxs-emverm-approved-for-parasitic-worm-infestations-2016-01-19", "https://www.nasdaq.com/articles/best-value-stocks-2015-2016-01-03", "https://www.nasdaq.com/articles/15-best-stocks-ring-out-old-ring-new-2015-12-31", "https://www.nasdaq.com/articles/ligand-lgnd-upgraded-to-buy-perfect-for-your-portfolio-2015-12-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-amgen-ligand-pharmaceuticals-revance", "https://www.nasdaq.com/articles/5-biotech-stocks-doubled-2015-2016-01-07", "https://www.nasdaq.com/articles/vicals-vl-2397-gets-orphan-status-for-invasive-aspergillosis-2016-01-07", "https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-sbla-to-face-final-decision-2016-01-04", "https://www.nasdaq.com/articles/biomarin-reveals-interim-data-from-pompe-disease-study-2016-01-12", "https://www.nasdaq.com/articles/what-awaits-ligand-pharmaceuticals-lgnd-in-q3-earnings-2015-11-05", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-evomela-gets-crl-in-the-u.s.-2015-10-23", "https://www.nasdaq.com/articles/heres-why-spectrum-pharmaceuticals-stock-plunged-today-2015-10-23", "https://www.nasdaq.com/articles/ligand-sage-captisol-partnership-to-also-include-sage-689-2015-09-30", "https://www.nasdaq.com/articles/fastest-growing-biotech-stocks-2015-09-21", "https://www.nasdaq.com/articles/novartis-nvs-promacta-label-further-expanded-in-u.s.-2015-08-26", "https://www.nasdaq.com/articles/relative-strength-alert-ligand-pharmaceuticals-2015-08-24", "https://www.nasdaq.com/articles/ligand-lgnd-beats-on-q3-earnings-lowers-2015-outlook-2015-11-10", "https://www.nasdaq.com/articles/collegiums-xtampza-to-be-reviewed-by-fda-advisory-panels-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/syntas-q2-loss-narrower-than-expected-focus-on-pipeline-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/mylan-beats-on-q2-earnings-revenues-in-line-guidance-up-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/dan-loeb-sees-opportunity-latest-target-baxter-international-2015-08-06", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-misses-on-q2-earnings-affirms-view-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/surmodics-srdx-beats-on-q3-earnings-improves-outlook-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/perrigo-beats-on-q2-earnings-revenues-in-line-keeps-view-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/endo-beats-on-q2-earnings-and-revenues-maintains-view-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/mallinckrodt-beats-q3-earnings-transformation-in-progress-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/zoetis-beats-on-q2-earnings-and-revenues-narrows-view-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/regeneron-beats-on-q2-earnings-eylea-2015-view-upped-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/biomarin-q2-loss-narrower-than-expected-maintains-outlook-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-beat-earnings-in-q2-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/qlt-qlti-reports-wider-than-expected-loss-in-q2-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/vivus-vvus-q2-loss-narrower-restructuring-announced-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-beats-on-q2-earnings-affirms-view-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/tevas-q2-earnings-revenues-beat-expectations-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/acorda-2q-earnings-revenues-top-ampyra-focus-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/bayer-bayry-q2-revenues-up-y-y-2015-guidance-revised-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/vertex-posts-wider-yy-loss-raises-kalydeco-outlook-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/theravances-q2-loss-wider-than-expected-revenues-miss-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/alexion-misses-on-earnings-in-q2-2015-outlook-revised-analyst-blog-2015-07-30", "https://www.nasdaq.com/articles/united-therapeutics-misses-q2-earnings-revenues-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/amgen-beats-q2-earnings-revenues-raises-outlook-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/tevas-q2-earnings-revenues-beat-expectations-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/acorda-2q-earnings-revenues-top-ampyra-focus-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/commit-purchase-ligand-pharmaceuticals-75-earn-67-annualized-using-options-2015-07-24", "https://www.nasdaq.com/articles/biogen-tops-q2-earnings-cuts-view-tecfidera-issues-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/abbvie-tops-earnings-misses-revenues-maintains-view-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/xoma-crashes-after-gevokizumab-misses-primary-endpoint-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/perrigo-prgo-to-buy-yokebe-brand-boost-eu-presence-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q2-earnings-raises-2015-outlook-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/hospira-hsp-beats-on-q2-earnings-driven-by-strong-sales-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/commit-purchase-ligand-pharmaceuticals-75-earn-67-annualized-using-options-2015-07-24", "https://www.nasdaq.com/articles/novartis-malaria-drug-gets-who-nod-for-public-procurement-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/bristol-myers-inks-another-fibrotic-disease-agreement-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/why-ligand-pharmaceuticals-lgnd-could-be-an-impressive-growth-stock-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/mercks-anti-pd-1-therapy-melanoma-drug-gets-eu-nod-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/eli-lilly-beats-2q-earnings-wide-margin-ups-view-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/illumina-tops-q2-earnings-misses-on-revenues-eps-view-up-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/bristol-myers-hiv-1-inhibitor-gets-breakthrough-designation-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/horizon-pharma-up-on-expected-q2-sales-2015-outlook-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/novartis-malaria-drug-gets-who-nod-for-public-procurement-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/bristol-myers-inks-another-fibrotic-disease-agreement-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/why-ligand-pharmaceuticals-lgnd-could-be-an-impressive-growth-stock-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/mercks-anti-pd-1-therapy-melanoma-drug-gets-eu-nod-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/cytokinetics-advances-tirasemtiv-to-phase-iii-shares-up-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/qiagens-egfr-test-gets-pma-nod-to-treat-lung-cancer-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/3-biotech-stocks-could-grow-faster-apple-2015-07-04", "https://www.nasdaq.com/articles/why-ligand-pharmaceuticals-lgnd-could-be-positioned-for-a-surge-tale-of-the-tape-2015-06", "https://www.nasdaq.com/articles/health-care-sector-update-06122015-crbp-lgnd-prta-2015-06-12", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-reports-type-ii-diabetes-drug-data-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-updates-viking-ipo-ups-2015-view-analyst-blog-2015-06-03", "https://www.nasdaq.com/articles/aratanas-petx-pain-drug-for-dogs-effective-in-pivotal-study-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/3-best-breed-biotech-stocks-2015-05-30", "https://www.nasdaq.com/articles/interesting-lgnd-put-and-call-options-june-19th-2015-04-21", "https://www.nasdaq.com/articles/health-care-sector-update-04202015-cldx-lgnd-lly-2015-04-20", "https://www.nasdaq.com/articles/its-hip-be-repaired-viking-therapeutics-refiles-terms-20-million-ipo-2015-04-10", "https://www.nasdaq.com/articles/3-and-coming-biotech-stocks-watch-2015-03-29", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-biotechs-jack-all-trades-2015-03-25", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-ce-melphalan-under-review-analyst-blog-2015-03-10", "https://www.nasdaq.com/articles/us-ipo-weekly-recap-4-ipos-offer-dividends-and-drugs-2015-05-01", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-lgnd-2015-02-24", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-posts-in-line-q4-earnings-tale-of-the-tape-2015-02-09", "https://www.nasdaq.com/articles/glaxo-submits-another-revolade-application-in-the-eu-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-miss-on-earnings-in-q4-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-breaks-above-200-day-moving-average-bullish-lgnd-2015-01-26", "https://www.nasdaq.com/articles/spectrum-ligand-pharma-seek-fda-nod-for-ce-melphalan-analyst-blog-2014-12-29", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-shares-fall-on-q3-earnings-miss-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-15.5-tale-of-the-tape-2015-03-03", "https://www.nasdaq.com/articles/sector-update-health-care-2014-10-27-0", "https://www.nasdaq.com/articles/ligand-lgnd-shares-march-higher-can-it-continue-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-ligand-lgnd-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/will-pfizer-pfe-disappoint-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/will-merck-mrk-pull-a-surprise-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-beat-q3-earnings-estimates-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/will-amgen-amgn-disappoint-in-the-q3-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/sector-update-health-care-shares-flat-opening-bell-2014-10-27", "https://www.nasdaq.com/articles/sector-update-health-care-2014-10-27-0", "https://www.nasdaq.com/articles/ligand-lgnd-shares-march-higher-can-it-continue-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-ligand-lgnd-tale-of-the-tape-2014-10-24", "https://www.nasdaq.com/articles/will-pfizer-pfe-disappoint-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/will-merck-mrk-pull-a-surprise-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/will-agenus-agen-incur-wider-than-expected-q3-loss-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/amgen-gains-as-third-point-suggests-split-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/will-vertex-pharmaceuticals-vrtx-post-a-lower-q3-loss-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/can-epizyme-epzm-surprise-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/omeros-falls-as-enrollment-for-oms824-study-is-suspended-analyst-blog-2014-10-23", "https://www.nasdaq.com/articles/actelion-misses-q3-earnings-expectation-ups-2014-guidance-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-wins-fda-panel-backing-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-disappoint-this-earnings-season-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/will-agenus-agen-incur-wider-than-expected-q3-loss-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/amgen-gains-as-third-point-suggests-split-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/biogens-q3-earnings-top-estimates-view-raised-again-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/why-ligand-pharmaceuticals-lgnd-isnt-done-growing-earnings-yet-tale-of-the-tape-2014-10-21", "https://www.nasdaq.com/articles/pacific-biosciences-to-incur-narrower-than-expected-q3-loss-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/will-biomarin-bmrn-disappoint-this-earnings-season-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/will-alexion-alxn-earnings-suffer-due-to-higher-costs-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/celgene-celg-q3-earnings-to-be-overrun-by-expenses-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/will-sangamo-sgmo-incur-wider-than-expected-q3-loss-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/will-glaxosmithkline-gsk-earnings-suffer-on-china-probe-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/biogens-q3-earnings-top-estimates-view-raised-again-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-crush-estimates-at-its-next-earnings-report-tale-of-the", "https://www.nasdaq.com/articles/gw-pharmaceuticals-down-on-disappointing-mid-stage-data-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/mallinckrodt-gives-fy15-guidance-post-questcor-acquisition-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/abbvie-reconsiders-shire-acquisition-due-to-new-tax-rules-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/alnylam-reveals-positive-data-from-its-pipeline-candidates-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/newlink-genetics-nlnk-shows-strength%3A-stock-up-23.7-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/cyclacel-provides-seamless-study-update-on-sapacitabine-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/orexigen-100m-milestone-payment-takeda-analyst-blog-2014-10-16", "https://www.nasdaq.com/articles/will-ligand-pharmaceuticals-lgnd-crush-estimates-at-its-next-earnings-report-tale-of-the", "https://www.nasdaq.com/articles/will-johnson-johnson-beat-earnings-on-pharma-sales-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/weakness-seen-in-momenta-pharmaceuticals-mnta%3A-stock-tumbles-13.5-tale-of-the-tape-2014-10", "https://www.nasdaq.com/articles/amgens-blinatumomab-gets-priority-review-in-the-u.s.-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/prosensa-starts-rolling-nda-submission-for-drisapersen-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/targacepts-nine-year-association-with-astrazeneca-to-end-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/abbvies-humira-positive-in-late-stage-skin-disease-study-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/pfizers-breast-cancer-candidate-gets-priority-review-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/alnylam-jumps-on-positive-patisiran-data-from-phase-ii-study-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/will-johnson-johnson-beat-earnings-on-pharma-sales-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/weakness-seen-in-momenta-pharmaceuticals-mnta%3A-stock-tumbles-13.5-tale-of-the-tape-2014-10", "https://www.nasdaq.com/articles/halozymes-pegph20-receives-fda-orphan-drug-designation-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/eli-lilly-stops-developing-tabalumab-due-to-efficacy-issues-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/astrazenecas-benralizumab-encourages-in-phase-ii-study-analyst-blog-2014-10-10", "https://www.nasdaq.com/articles/xoma-starts-phase-i-study-on-xoma-358-for-hyperinsulinism-analyst-blog-2014-10-10", "https://www.nasdaq.com/articles/ligand-provides-better-than-expected-q3-earnings-guidance-analyst-blog-2014-10-09", "https://www.nasdaq.com/articles/amgen-up-on-positive-phase-iii-data-on-psoriasis-biosimilar-analyst-blog-2014-10-09", "https://www.nasdaq.com/articles/dow-surges-over-200-points-after-fomc-minutes-blackhawk-shares-jump-strong-results-2014-10", "https://www.nasdaq.com/articles/interface-drops-q3-warning-symantec-shares-rise-2014-10-08", "https://www.nasdaq.com/articles/diabetes-biotech-viking-therapeutics-sets-terms-55-million-ipo-2014-09-02", "https://www.nasdaq.com/articles/ligand-up-on-multi-program-captisol-deal-with-avion-pharma-analyst-blog-2014-08-18", "https://www.nasdaq.com/articles/abbvies-humira-label-expanded-in-u.s.-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/insiders-now-seeing-red-lgnd-new-52-week-low-2014-10-07", "https://www.nasdaq.com/articles/ligand-earns-milestone-payment-on-eu-approval-of-noxafil-analyst-blog-2014-10-02", "https://www.nasdaq.com/articles/commit-purchase-ligand-pharmaceuticals-40-earn-218-annualized-using-options-2014-09-22", "https://www.nasdaq.com/articles/nasdaq-biotechnology-top-performers-market-open-september-11-2014-09-11", "https://www.nasdaq.com/articles/ligand-inks-2nd-captisol-deal-with-curx-pharmaceuticals-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/diabetes-biotech-viking-therapeutics-sets-terms-55-million-ipo-2014-09-02", "https://www.nasdaq.com/articles/ligand-up-on-multi-program-captisol-deal-with-avion-pharma-analyst-blog-2014-08-18", "https://www.nasdaq.com/articles/abbvies-humira-label-expanded-in-u.s.-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-up-10.1-tale-of-the-tape-2014-08-05", "https://www.nasdaq.com/articles/glaxos-promacta-in-phase-iii-for-mds-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/ligand-pharma-tg-therapeutics-collaborate-on-irak4-inhibitors-analyst-blog-2014-06-25", "https://www.nasdaq.com/articles/interesting-lgnd-put-and-call-options-november-22nd-2014-06-17", "https://www.nasdaq.com/articles/glaxos-promacta-holds-promise-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/ligand-pharmas-lgd-6972-positive-in-phase-i-study-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/spectrum-pharma-candidate-gets-positive-data-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/milestone-payment-for-ligand-pharma-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/bright-outlook-at-ligand-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/glaxo-ligand-look-to-expand-promacta-label-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/update-on-ligand-glaxos-promacta-analyst-blog-2014-02-05", "https://www.nasdaq.com/articles/update-on-glaxos-portfolio-analyst-blog-2013-09-26", "https://www.nasdaq.com/articles/insiders-chefs-warehouse-buy-shares-while-ligand-pharmaceuticals-sees-sale-2013-09-26", "https://www.nasdaq.com/articles/ligand-curx-collaborate-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-5.5-tale-of-the-tape-2013-11-27", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/glaxos-promacta-label-expanded-analyst-blog-2012-11-20", "https://www.nasdaq.com/articles/upcoming-biopharma-catalyst-trades-consider-2012-11-15", "https://www.nasdaq.com/articles/the-medicines-co.-halts-mdco-2010-analyst-blog-2012-10-08", "https://www.nasdaq.com/articles/mdcos-cangrelor-enrollment-by-4q-analyst-blog-2012-07-03", "https://www.nasdaq.com/articles/glaxo-aims-to-expand-promacta-label-analyst-blog-2012-06-01", "https://www.nasdaq.com/articles/stock-market-overheated-heres-my-plan-2012-03-26", "https://www.nasdaq.com/articles/ligand-azure-collaborate-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/week-biotech-more-treats-tricks-2009-11-01", "https://www.nasdaq.com/articles/low-risk-pick-my-100000-real-money-portfolio-2012-02-09"], "Content": []}